MOLECULAR GAUGE BLOCKS FOR BUILDING ON THE NANOSCALE (Fri, 17 May 2013)
<p id="p-0001" num="0000">Disclosed herein is a way to produce a series of discrete sized slender, rigid oligoparaxylene molecules ranging from 1-5 nm in length. Molecules, based on 1-7, 9-11 paraxylene rings, have been synthesized as part of a homologous series of oligoparaxylenes (OPXs) with a view to providing a molecular tool box for the construction of nano architectures—such as spheres, cages, capsules, metal-organic frameworks (MOFs), metal-organic polyhedrons (MOPs) and covalent-organic frameworks (COFs), to name but a few—of well-defined sizes and shapes. Twisting between the planes of contiguous paraxylene rings is generated by the steric hindrance associated with the methyl groups and leads to the existence of soluble molecular gauge blocks without the need—at least in the case of the lower homologues—to introduce long aliphatic side chains onto the phenylene rings in the molecules.</p>
>> read more

(Fri, 03 May 2013)

>> read more

NMDA RECEPTOR MODULATORS AND USES THEREOF (Fri, 03 May 2013)
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
>> read more

SYSTEM AND METHOD FOR GENERATING AND/OR SCREENING POTENTIAL METAL-ORGANIC FRAMEWORKS (Fri, 26 Apr 2013)
A system and method for systematically generating potential metal-organic framework (MOFs) structures given an input library of building blocks is provided herein. One or more material properties of the potential MOFs are evaluated using computational simulations. A range of material properties (surface area, pore volume, pore size distribution, powder x-ray diffraction pattern, methane adsorption capability, and the like) can be estimated, and in doing so, illuminate unidentified structure-property relationships that may only have been recognized by taking a global view of MOF structures. In addition to identifying structure-property relationships, this systematic approach to identify the MOFs of interest is used to identify one or more MOFs that may be useful for high pressure methane storage.
>> read more

SYSTEM AND METHOD FOR GENERATING AND/OR SCREENING POTENTIAL METAL-ORGANIC FRAMEWORKS (Fri, 26 Apr 2013)
A system and method for systematically generating potential metal-organic framework (MOFs) structures given an input library of building blocks is provided herein. One or more material properties of the potential MOFs are evaluated using computational simulations. A range of material properties (surface area, pore volume, pore size distribution, powder x-ray diffraction pattern, methane adsorption capability, and the like) can be estimated, and in doing so, illuminate unidentified structure-property relationships that may only have been recognized by taking a global view of MOF structures. In addition to identifying structure-property relationships, this systematic approach to identify the MOFs of interest is used to identify one or more MOFs that may be useful for high pressure methane storage.
>> read more

MODULAR SUPRAMOLECULAR APPROACH FOR CO-CRYSTALLIZATION OF DONORS AND ACCEPTORS INTO ORDERED NETWORKS (Fri, 22 Mar 2013)
<p id="p-0001" num="0000">Organic charge-transfer (CT) co-crystals in a mixed stack system are disclosed, wherein a donor molecule (D) and an acceptor molecule (A) occupy alternating positions (DADADA) along the CT axis. A platform is provided which amplifies the molecular recognition of donors and acceptors and produces co-crystals at ambient conditions, wherein the platform comprises (i) a molecular design of the first constituent (α-complement), (ii) a molecular design of the second compound (β-complement), and (iii) a solvent system that promotes co-crystallization.</p>
>> read more

FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS (Fri, 22 Mar 2013)
<p id="p-0001" num="0000">The invention relates to chemical compounds, compositions and methods of making and using the same. In particular, the invention provides selected pyridazine compounds of the formula I wherein R1, R4, R5, R6, R7, R8, R9, R12, R13 ET R14 are independently hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, amino, imino, azido, thiol, thioallyl, thioalkoxy, thioaryl, nitro, cyano, halo, sulfate, sulfonyl, sulfinyl, sulfonyl, sultanate, sulfoxide, silyl, silyloxy, silylalkyl, silylthio, =0, ═S, phosphonate, ureido, carboxyl, carbonyl, carbamoyl, or carboxamide; and X is optionally substituted pyrimidinyl or pyridazinyl, an isomer, a pharmaceutically acceptable salt, or derivative thereof. The invention additional relates to compositions comprising the compounds, and methods of using the compounds and compositions for modulation of cellular pathways, for treatment or prevention of inflammatory diseases, for research, drug screening, and therapeutic applications.</p> <p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"> <img id="EMI-C00001" he="24.72mm" wi="69.60mm" file="US20130072496A1-20130321-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/> </chemistry> </p>
>> read more

Tetratopic Phenyl Compounds, Related Metal-Organic Framework Materials and Post-Assembly Elaboration (Fri, 15 Mar 2013)
<p id="p-0001" num="0000">Disclosed are tetratopic carboxylic acid phenyl for use in metal-organic framework compounds. These compounds are useful in catalysis, gas storage, sensing, biological imaging, drug delivery and gas adsorption separation.</p>
>> read more

Aminopyridine dimer compounds, compositions and related methods for neuronal nitric oxide synthase inhibition (Fri, 15 Feb 2013)
<p id="p-0001" num="0000">Nitric oxide synthase (NOS) inhibitor compounds comprising bi-terminal aromatic ring moieties, and related methods of NOS inhibition.</p>
>> read more

BARRIERS FOR FACILITATING BIOLOGICAL REACTIONS (Fri, 08 Feb 2013)
<p id="p-0001" num="0000">The present invention relates to systems, devices, and methods for performing biological reactions. In particular, the present invention relates to the use of lipophilic, water immiscible, or hydrophobic barriers in sample separation, purification, modification, and analysis processes.</p>
>> read more

SUBSTRATE-INDEPENDENT LAYER-BY-LAYER ASSEMBLY USING CATECHOL-FUNCTIONALIZED POLYMERS (Fri, 18 Jan 2013)
<p id="p-0001" num="0000">The present invention provides a simple, non-destructive and versatile method that enables layer-by-layer (LbL) assembly to be performed on virtually any substrate. A novel catechol-functionalized polymer which adsorbs to virtually all surfaces and can serve as a platform for LbL assembly in a surface-independent fashion is also provided.</p>
>> read more

MODULAR SUPRAMOLECULAR APPROACH FOR CO-CRYSTALLIZATION OF DONORS AND ACCEPTORS INTO ORDERED NETWORKS (Fri, 30 Nov 2012)
Organic charge-transfer (CT) co-crystals in a mixed stack system are disclosed, wherein a donor molecule (D) and an acceptor molecule (A) occupy alternating positions (DADADA) along the CT axis. A platform is provided which amplifies the molecular recognition of donors and acceptors and produces co-crystals at ambient conditions, wherein the platform comprises (i) a molecular design of the first constituent (α- complement), (ii) a molecular design of the second compound ( β-complement), and (iii) a solvent system that promotes co-crystallization.
>> read more

PH RESPONSIVE SELF-HEALING HYDROGELS FORMED BY BORONATE-CATECHOL COMPLEXATION (Fri, 23 Nov 2012)
Biocompatible hydrogels made from cross-linked catechol-borate ester polymers are disclosed, along with methods of synthesizing and using such hydrogels. The hydrogels of the present invention are prepared by boronic acid-catechol complexation between catechol- containing macromonomers and boronic acid-containing cross-linkers. The resulting hydrogels are pH-responsive and self-healing, and can be used in a number of different biomedical applications, including in surgical implants, in surgical adhesives, and in drug delivery systems is data provides further evidence of the viability of using the disclosed hydrogels for in vivo in biomedical applications.
>> read more

SEMICONDUCTING COMPOUNDS AND DEVICES INCORPORATING SAME (Fri, 28 Sep 2012)
Disclosed are molecular and polymeric compounds having desirable properties as semiconducting materials. Such compounds can exhibit desirable electronic properties and possess processing advantages including solution-processability and/or good stability. Organic transistor and photovoltaic devices incorporating the present compounds as the active layer exhibit good device performance.
>> read more

INJECTABLE THERMORESPONSIVE POLYELECTROLYTES (Fri, 10 Aug 2012)
Provided herein are compositions, devices, and systems comprising thermoresponsive, biodegradable elastomeric materials, and methods of use and manufacture thereof.
>> read more

METHOD FOR PRODUCING SILYL-FUNCTIONALIZED POLYOLEFINS AND SILYL-FUNCTIONALIZED POLYOLEFINS WITH SILYL MONOMER INCORPORATION (Fri, 27 Jul 2012)
Methods for producing a silyl-functionalized polyolefin with silyl monomer incorporation are provided. The method includes reacting a silicon-containing olefin with an α-olefin, in the presence of a catalytic amount of a group IV catalyst for a time sufficient to produce a silyl-functionalized polyolefin.
>> read more

SELECTIVE CALCIUM CHANNEL ANTAGONISTS (Fri, 27 Jul 2012)
The present invention relates to compositions and methods for the treatment and/or prevention of neurodegenerative disorders, e.g., Parkinson's disease (PD). In particular, the present invention provides compositions comprising selective antagonists of calcium ion channels (e.g., cav 1.3 -type ion channels), and methods of use thereof to treat or prevent neurodegenerative disorders.
>> read more

Thermo-gelling matrices and related methods for microchannel DNA sequencing (Wed, 04 Jul 2012)
<p id="p-0001" num="0000">Polymeric compounds and related methods and apparatus, as can be used in a wide range of RNA and DNA separations.</p>
>> read more

METAL-ORGANIC FRAMEWORKS FOR XE/KR SEPARATION (Fri, 24 Feb 2012)
Metal-organic framework (MOF) materials are provided and are selectively adsorbent to xenon (Xe) over another noble gas such as krypton (Kr) and/or argon (Ar) as a result of having framework voids (pores) sized to this end. MOF materials having pores that are capable of accommodating a Xe atom but have a small enough pore size to receive no more than one Xe atom are desired to preferentially adsorb Xe over Kr in a multi-component (Xe-Kr mixture) adsorption method. The MOF material has 20% or more, preferably 40% or more, of the total pore volume in a pore size range of 0.45-0.75 nm which can selectively adsorb Xe over Kr in a multi-component Xe-Kr mixture over a pressure range of 0.01 to 1.0 MPa.
>> read more

CHIRAL SYNTHESIS OF PYRROLIDINE CORE COMPOUNDS EN ROUTE TO NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS (Fri, 06 Jan 2012)
A chiral synthesis of pyrrolidine compounds en route to seletive neuronal nitric oxide synthase inhibitors, and representative inhibitor compounds heretofore unattainable.
>> read more

RECOMBINANT LACTOBACILLUS WITH DECREASED LIPOTEICHOIC ACID TO REDUCE INFLAMMATORY RESPONSES (Fri, 23 Dec 2011)
Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease.
>> read more

Barriers for facilitating biological reactions (Fri, 16 Dec 2011)
<p id="p-0001" num="0000">The present invention relates to systems, devices, and methods for performing biological reactions. In particular, the present invention relates to the use of lipophilic, water immiscible, or hydrophobic barriers in sample separation, purification, modification, and analysis processes.</p>
>> read more

ORGANIC-INORGANIC HYBRID MULTILAYER GATE DIELECTRICS FOR THIN-FILM TRANSISTORS (Fri, 25 Nov 2011)
Disclosed are organic-inorganic hybrid self-assembled multilayers that can be used as electrically insulating (or dielectric) materials. These multilayers generally include an inorganic primer layer and one or more bilayers deposited thereon. Each bilayer includes a chromophore or "π-polarizable" layer and an inorganic capping layer composed of zirconia. Because of the regularity of the bilayer structure and the aligned orientation of the chromophore resulting from the self-assembly process, the present multilayers have applications in electronic devices such as thin film transistors, as well as in nonlinear optics and nonvolatile memories.
>> read more

Twisted π-electron system chromophore compounds with very large molecular hyperpolarizabilities and related compositions and devices (Fri, 18 Nov 2011)
<p id="p-0001" num="0000">Unconventional twisted π-electron system electro-optic (EO) chromophores/compounds, compositions and related device structures. Crystallographic analysis of several non-limiting chromophores reveals, for instance, large ring-ring dihedral twist angles and a highly charge-separated zwitterionic structure in the ground state, in both solution phase and solid-state.</p>
>> read more

Barriers for facilitating biological reactions (Fri, 04 Nov 2011)
<p id="p-0001" num="0000">The present invention relates to systems, devices, and methods for performing biological reactions. In particular, the present invention relates to the use of lipophilic, water immiscible, or hydrophobic barriers in sample separation, purification, modification, and analysis processes.</p>
>> read more

ORGANIC PHOTOVOLTAIC DEVICE WITH INTERFACIAL LAYER AND METHOD OF FABRICATING SAME (Fri, 04 Nov 2011)
An organic photovoltaic device and method of forming same. In one embodiment, the organic photovoltaic device has an anode, a cathode, an active layer disposed between the anode and the cathode; and an interfacial layer disposed between the anode and the active layer, the interfacial layer comprising 5,5'-bis[(p-trichlorosilylpropylphenyl)phenylamino]-2,2'-bithiophene (PABTSi2).
>> read more

CATALYST AND BYPRODUCT-FREE NATIVE CHEMICAL LIGATION USING CYCLIC THIOESTER PRECURSORS (Fri, 28 Oct 2011)
<p id="p-0001" num="0000">A method of synthesizing a biocompatible hydrogel by covalently cross-linking an effective amount of a first macromonomer including a cyclic thioester group with an effective amount of a second macromonomer including a terminal cysteine group is disclosed. In addition, the synthesis and use of the following specific cyclic thioester macromonomer that can be used in the method, as well as specific hydrogels made using this macromonomer are disclosed. The disclosed method produces a biocompatible hydrogel, while producing substantially no toxic free thiol by-product. Accordingly, the method can be used in making biomedical products, such as sutures and tissue replacement biomaterials, and for encapsulating therapeutic cells and pharmaceuticals.</p>
>> read more

TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (Fri, 30 Sep 2011)
<p id="p-0001" num="0000">The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.</p>
>> read more

CONJUGATED POLYMERS AND DEVICES INCORPORATING SAME (Fri, 30 Sep 2011)
Disclosed are conjugated polymers having desirable properties as semiconducting materials. Such polymers can exhibit desirable electronic properties and possess processing advantages including solution-processability and/or good stability.
>> read more

NANOPOROUS CARBOHYDRATE FRAMEWORKS AND THE SEQUESTRATION AND DETECTION OF MOLECULES USING THE SAME (Fri, 23 Sep 2011)
Disclosed are cyclodextrin-based metal organic frameworks comprising a metal cation and cyclodextrin or a cyclodextrin derivative. These metal organic frameworks are permanently porous and capable of molecule storage.
>> read more

SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF (Fri, 19 Aug 2011)
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain.
>> read more

PARAMAGNETIC METAL-NANODIAMOND CONJUGATES (Fri, 22 Jul 2011)
<p id="p-0001" num="0000">The present invention provides compositions and methods for the synthesis of conjugates of paramagnetic metal ions and nanodiamonds, and uses thereof. In particular, the present invention provides synthesis of paramagnetic metal-nanodiamond conjugates and methods using such compositions as molecular imaging probes.</p>
>> read more

Layer by layer self-assembly of large response molecular electro-optic materials by a desilylation strategy (Wed, 13 Jul 2011)
<p id="p-0001" num="0000">The preparation of robust, thin film materials with large second-order optical nonlinearities through the covalent self-assembly of chromophoric compositions and innovative use of silyl chemistry.</p>
>> read more

Layer by layer self-assembly of large response molecular electro-optic materials by a desilylation strategy (Wed, 06 Jul 2011)
<p id="p-0001" num="0000">The preparation of robust, thin film materials with large second-order optical nonlinearities through the covalent self-assembly of chromophoric compositions and innovative use of silyl chemistry.</p>
>> read more

Activation of porous MOF materials (Fri, 17 Jun 2011)
<p id="p-0001" num="0000">A method for the treatment of solvent-containing MOF material to increase its internal surface area involves introducing a liquid into the MOF in which liquid the solvent is miscible, subjecting the MOF to supercritical conditions for a time to form supercritical fluid, and releasing the supercritical conditions to remove the supercritical fluid from the MOF. Prior to introducing the liquid into the MOF, occluded reaction solvent, such as DEF or DMF, in the MOF can be exchanged for the miscible solvent.</p>
>> read more

COMPOSITIONS AND METHODS FOR TREATING LYMPHOMA (Fri, 13 May 2011)
Provided are compositions comprising PX-478, or metabolites, analogs or derivatives thereof for treatment of lymphoma.
>> read more

TEMPLATED NANOCONJUGATES (Fri, 06 May 2011)
The present disclosure is directed to compositions comprising templated nanoconjugates and methods of their use.
>> read more

Nanomolar β-lactamase inhibitors (Wed, 20 Apr 2011)
<p id="p-0001" num="0000">New carboxyphenyl-glycylboronic acid transition-state analog inhibitors, representative of a class of compounds effective against class C β-lactamase AmpC. The new compounds improve inhibition by over two-orders of magnitude compared to analogous glycylboronic acids, with Ki values as low as 1 nM.</p>
>> read more

Solid phase host compositions (Wed, 30 Mar 2011)
<p id="p-0001" num="0000">A new family of silicon-based polymers has been prepared in which organic host components are bound covalently. The polymer is a polysilsesquioxane matrix comprising, for example, hosts such as cyclodextrins (CD) or calixarenes (CX).</p>
>> read more

Zinc-activated contrast agents (Wed, 16 Mar 2011)
<p id="p-0001" num="0000">The present invention relates to contrast agents for magnetic resonance imaging (MRI). In particular, the present invention relates to MRI contrast agents that are activated in the presence of zinc(II) (e.g., resulting in a brighter image).</p>
>> read more

POLYVALENT POLYNUCLEOTIDE NANOPARTICLE CONJUGATES AS DELIVERY VEHICLES FOR A CHEMOTHERAPEUTIC AGENT (Fri, 11 Mar 2011)
The present invention is directed to compositions and methods of delivering a chemotherapeutic agent via a polynueleotide-functionalized nanoparticle (PN-NP).
>> read more

CLICK CHEMISTRY, MOLECULAR TRANSPORT JUNCTIONS, AND COLORIMETRIC DETECTION OF COPPER (Fri, 11 Feb 2011)
<p id="p-0001" num="0000">Click chemistry is used to construct molecular transport junctions (MTJs) through assembly of a molecular wire across a nanogap formed between two electrodes. Also disclosed are methods of using click chemistry and oligonucleotide-modified nanoparticles to detect the presence of copper in a sample.</p>
>> read more

INTRACELLULAR DELIVERY OF CONTRAST AGENTS WITH FUNCTIONALIZED NANOPARTICLES (Fri, 11 Feb 2011)
The present invention is directed to compositions and methods for intracellular delivery of a contrast agent with a functionalized nanoparticle.
>> read more

Crosslinked polymeric dielectric materials and electronic devices incorporating same (Fri, 04 Feb 2011)
<p id="p-0001" num="0000">Solution-processable dielectric materials are provided, along with precursor compositions and processes for preparing the same. Composites and electronic devices including the dielectric materials also are provided.</p>
>> read more

SEALANTS FOR MEMBRANE REPAIR (Fri, 04 Feb 2011)
The present invention provides a method for preventing or repairing damage to a fetal membrane. In one embodiment, the method comprises contacting a fetal membrane with a composition comprising a four-armed catechol-terminated polyethylene glycol (cPEG) and a biocompatible oxidant, hi one embodiment, the four-armed cPEG and the biocompatible oxidant are initially contained in separate solutions, and the solutions are mixed to form the composition just prior to or at the same time that the composition contacts the fetal membrane.
>> read more

Self-assembly of peptide-amphiphile nanofibers under physiological conditions (Fri, 14 Jan 2011)
<p id="p-0001" num="0000">The present invention provides a method of promoting neuron growth and development by contacting cells with a peptide amphiphile molecule in an aqueous solution in the presence of a metal ion. According to the method, the peptide amphiphile forms a cylindrical micellar nanofiber composed of beta-sheets, which promote neuron growth and development.</p>
>> read more

Metastable Nanoparticle Ink Compositions and Images Made Therefrom (Fri, 31 Dec 2010)
<p id="p-0001-en" num="0000">Self-erasing inks in which both the printing and self-erasure of color images can be controlled by the dynamic/non-equilibrium aggregation of photoresponsive surface-coated nanoparticles contained in a carrier film are provided. The aggregation is a reversible aggregation that is triggered by a photo-induced transformation in ligands within the surface coating on the nanoparticles. Methods for forming images using the inks are also provided.</p>
>> read more

Surface Independent, Surface-Modifying, Multifunctional Coatings and Applications Thereof (Fri, 31 Dec 2010)
<p id="p-0001-en" num="0000">The invention provides surface treatments that reduce or eliminate marine biofouling of various surfaces. A surface that is to be subjected to a marine environment can be treated with a mPEG-DOPA. The treated surface is thus rendered less susceptible to fouling of the surface.</p>
>> read more

Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death (Fri, 17 Dec 2010)
<p id="p-0001" num="0000">A novel class of pyridazine compositions and related methods of use.</p>
>> read more

Anti-cancer compounds (Fri, 03 Dec 2010)
<p id="p-0001" num="0000">The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation.</p>
>> read more

TARGETED SCHIFF BASE COMPLEXES (Fri, 26 Nov 2010)
<p id="p-0001-en" num="0000">The present invention provides targeted Schiff base complexes. In particular the present invention provides biopolymer targeted transition metal complexes configured to inhibit the activity of targeted proteins, methods of synthesis thereof, and pharmaceutical compositions and uses thereof.</p>
>> read more

CHIRAL PYRROLIDINE CORE COMPOUNDS EN ROUTE TO INHIBITORS OF NITRIC OXIDE SYNTHASE (Fri, 19 Nov 2010)
Diastereomeric pyrrolidine compounds and methods of preparation, as can be used en route to the preparation of a range of nitric oxide synthase inhibitors.
>> read more

Twisted π-electron system chromophore compounds with very large molecular hyperpolarizabilities and related compositions and devices (Fri, 29 Oct 2010)
<p id="p-0001" num="0000">Unconventional twisted π-electron system electro-optic (EO) chromophores/compounds, compositions and related device structures. Crystallographic analysis of several non-limiting chromophores reveals, for instance, large ring-ring dihedral twist angles and a highly charge-separated zwitterionic structure in the ground state, in both solution phase and solid-state.</p>
>> read more

Purification of metal-organic framework materials (Fri, 22 Oct 2010)
<p id="p-0001" num="0000">A method of purification of a solid mixture of a metal-organic framework (MOF) material and an unwanted second material by disposing the solid mixture in a liquid separation medium having a density that lies between those of the wanted MOF material and the unwanted material, whereby the solid mixture separates by density differences into a fraction of wanted MOF material and another fraction of unwanted material.</p>
>> read more

Organic photovoltaic device with interfacial layer and method of fabricating same (Fri, 08 Oct 2010)
<p id="p-0001" num="0000">An organic photovoltaic device and method of forming same. In one embodiment, the organic photovoltaic device has an anode, a cathode, an active layer disposed between the anode and the cathode; and an interfacial layer disposed between the anode and the active layer, the interfacial layer comprising 5,5′-bis[(p-trichlorosilylpropylphenyl)phenylamino]-2,2′-bithiophene (PABTSi₂).</p>
>> read more

TARGETED SCHIFF BASE COMPLEXES (Fri, 01 Oct 2010)
The present invention provides targeted Schiff base complexes. In particular the present invention provides biopolymer targeted transition metal complexes configured to inhibit the activity of targeted proteins, methods of synthesis thereof, and pharmaceutical compositions and uses thereof.
>> read more

COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS (Fri, 20 Aug 2010)
<p id="p-0001-en" num="0000">The present invention relates to therapeutic and/or prophylactic uses of pyridazine compounds and to pharmaceutical compositions containing one or more of these compounds as an active component for treating a disorder characterized by conduction disturbances, electroconvulsions and/or seizures, in particular epilepsy, more particularly pediatric epilepsy. In an aspect of the invention, the pyridnsine compound has the Formula (Ia) or (Ib) wherein R¹, R², R³, R⁴, R⁵, R⁶and R⁷are as defined in the description.</p> <p id="p-0002-en" num="0000"> <chemistry id="chem-us-00001-en" num="00001"> <img id="emi-c00001-en" he="92.54mm" wi="53.17mm" file="US20100210590A1-20100819-C00001.TIF" img-content="chem" img-format="tif"/> </chemistry> </p>
>> read more

AMINOPYRIDINE DIMER COMPOUNDS, COMPOSITIONS AND RELATED METHODS FOR NEURONAL NITRIC OXIDE SYNTHASE INHIBITION (Fri, 20 Aug 2010)
Nitric oxide synthase (NOS) inhibitor compounds comprising bi-terminal aromatic ring moieties, and related methods of NOS inhibition.
>> read more

Layer by layer self-assembly of large response molecular electro-optic materials by a desilylation strategy (Wed, 18 Aug 2010)
<p id="p-0001-en" num="0000">The preparation of robust, thin film materials with large second-order optical nonlinearities through the covalent self-assembly of chromophoric compositions and innovative use of silyl chemistry.</p>
>> read more

Cyclic peptide antitumor agents (Fri, 13 Aug 2010)
<p id="p-0001" num="0000">Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.</p>
>> read more

N-type semiconductors and related devices (Fri, 13 Aug 2010)
<p id="p-0001" num="0000">Mono- and diimide perylene and naphthalene compounds, N- and/or core-substituted with electron-withdrawing groups, for use in the fabrication of various device structures.</p>
>> read more

Potent and selective neuronal nitric oxide synthase inhibitors with improved membrane permeability (Fri, 30 Jul 2010)
<p id="p-0001" num="0000">Compounds and related compositions and methods as can be used to inhibit neuronal nitric oxide synthase and can be employed in the treatment of various neurodegenerative diseases, such compounds of a formula</p> <p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"> <img id="EMI-C00001" he="22.01mm" wi="69.26mm" file="US08299100-20121030-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/> </chemistry> </p>
>> read more

COMPOSITIONS AND METHODS FOR INDUCTION OF ANTIGEN-SPECIFIC TOLERANCE (Fri, 30 Jul 2010)
The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to induce antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect. The invention is useful for treatment of immune related disorders such as autoimmune disease, transplant rejection and allergic reactions.
>> read more

POTENT AND SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS WITH IMPROVED MEMBRANE PERMEABILITY (Fri, 30 Jul 2010)
Compounds and related compositions and methods as can be used to inhibit neuronal nitric oxide synthase and as can be employed in the treatment of various neurodegenerative diseases.
>> read more

Tetratopic phenyl compounds, related metal-organic framework materials and post-assembly elaboration (Fri, 09 Jul 2010)
<p id="p-0001" num="0000">Disclosed are tetratopic carboxylic acid phenyl for use in metal-organic framework compounds. These compounds are useful in catalysis, gas storage, sensing, biological imaging, drug delivery and gas adsorption separation.</p>
>> read more

Nanoscale lamellar photoconductor hybrids and methods of making same (Fri, 11 Jun 2010)
<p id="p-0001" num="0000">An article of manufacture and methods of making same. In one embodiment, the article of manufacture has a plurality of zinc oxide layers substantially in parallel, wherein each zinc oxide layer has a thickness d₁, and a plurality of organic molecule layers substantially in parallel, wherein each organic molecule layer has a thickness d₂and a plurality of molecules with a functional group that is bindable to zinc ions, wherein for every pair of neighboring zinc oxide layers, one of the plurality of organic molecule layers is positioned in between the pair of neighboring zinc oxide layers to allow the functional groups of the plurality of organic molecules to bind to zinc ions in the neighboring zinc oxide layers to form a lamellar hybrid structure with a geometric periodicity d₁+d₂, and wherein d₁and d₂satisfy the relationship of d₁≦d₂≦3d₁.</p>
>> read more

INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS (Fri, 04 Jun 2010)
<p id="p-0001-en" num="0000">The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4.</p>
>> read more

TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (Fri, 28 May 2010)
The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.
>> read more

Neutral bimetallic transition metal phenoxyiminato catalysts and related polymerization methods (Fri, 14 May 2010)
<p id="p-0001" num="0000">A catalyst composition comprising a neutral bimetallic diphenoxydiiminate complex of group 10 metals or Ni, Pd or Pt is disclosed. The compositions can be used for the preparation of homo- and co-polymers of olefinic monomer compounds.</p>
>> read more

TETRATOPIC PHENYL COMPOUNDS, RELATED METAL-ORGANIC FRAMEWORK MATERIALS AND POST-ASSEMBLY ELABORATION (Fri, 16 Apr 2010)
Disclosed are tetratopic carboxylic acid phenyl for use in metal-organic framework compounds. These compounds are useful in catalysis, gas storage, sensing, biological imaging, drug delivery and gas adsorption separation.
>> read more

INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS (Fri, 16 Apr 2010)
The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4.
>> read more

Method of synthesizing acetonide-protected catechol-containing compounds and intermediates produced therein (Fri, 09 Apr 2010)
<p id="p-0001" num="0000">The inventors disclose here a novel, facile approach to the synthesis of acetonide-protected catechol-containing compounds having at least one amine group. In specific embodiments, the invention provides novel methods of synthesizing 3,4-dihydroxyphenylalanine (H-DOPA(acetonide)-OH (6)), Fmoc-protected H-DOPA(acetonide)-OH (Fmoc-DOPA(acetonide)-OH (7)), Fmoc-protected dopamine (Fmoc-dopamine(acetonide) (10)), TFA-protected dopamine (TFA-dopamine(acetonide) (13)) and acetonide-protected 4-(2-aminoethyl)benzene-1,2-diol (acetonide-protected dopamine (14)).</p>
>> read more

Thermo-gelling matrices for microchannel DNA sequencing (Wed, 24 Mar 2010)
<p id="p-0001-en" num="0000">Polymeric compounds and related methods and apparatus, as can be used in a wide range of RNA and DNA separations.</p>
>> read more

METHOD FOR REDUCING SCARRING DURING WOUND HEALING USING ANTISENSE COMPOUNDS DIRECTED TO CTGF (Fri, 12 Mar 2010)
This invention provides a method for reducing hypertropic scarring resulting from dermal wound healing in a subject in need which comprises administering to the subject an antisense oligonucleotide which inhibits expression of connective tissue growth factor (CTGF) in an amount effective to inhibit expression of CTGF and thereby reduce hypertrophic scarring.
>> read more

METHOD FOR REDUCING SCARRING DURING WOUND HEALING USING ANTISENSE COMPOUNDS DIRECTED TO CTGF (Fri, 12 Mar 2010)
This invention provides a method for reducing hypertropic scarring resulting from dermal wound healing in a subject in need which comprises administering to the subject an antisense oligonucleotide which inhibits expression of connective tissue growth factor (CTGF) in an amount effective to inhibit expression of CTGF and thereby reduce hypertrophic scarring.
>> read more

Pathogenecity Islands of Pseudomonas Aeruginosa (Fri, 05 Mar 2010)
<p id="p-0001-en" num="0000">Disclosed are <i>Pseudomonas aeruginosa </i>Genomic Island nucleic acid sequences referred to as PAGI-5, PAGI-6, PAGI-7, PAGI-8, PAGI-9, PAGI-10, and PAGI-11. These nucleic acid sequences may be useful in methods for identifying virulent strains of <i>Pseudomonas </i>bacteria.</p>
>> read more

Silole-based polymers and semiconductor materials prepared from the same (Fri, 05 Feb 2010)
<p id="p-0001-en" num="0000">The present teachings provide silole-based polymers that can be used as p-type semiconductors. More specifically, the present teachings provide polymers that include a repeating unit of Formula I:</p> <p id="p-0002-en" num="0000"> <chemistry id="chem-us-00001-en" num="00001"> <img id="emi-c00001" he="35.73mm" wi="70.02mm" file="US07816480-20101019-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/> </chemistry> wherein R¹, R², R³, R⁴, R⁵R⁶, Z, x, and x′ are as defined herein. The present teachings also provide methods of preparing these polymers, and relate to various compositions, composites, and devices that incorporate these polymers. </p>
>> read more

COMPOSITIONS AND METHODS COMPRISING MAGNETIC RESONANCE CONTRAST AGENTS (Fri, 05 Feb 2010)
<p id="p-0001-en" num="0000">The present invention relates to compositions and methods for imaging with magnetic resonance contrast agents. In particular, the present invention provides targeted contrast agents for selective imaging.</p>
>> read more

Layer by layer self-assembly of large response molecular electro-optic materials by a desilylation strategy (Wed, 27 Jan 2010)
<p id="p-0001-en" num="0000">The preparation of robust, thin film materials with large second-order optical nonlinearities through the covalent self-assembly of chromophoric compositions and innovative use of silyl chemistry.</p>
>> read more

Modified acrylic block copolymers for hydrogels and pressure sensitive wet adhesives (Fri, 04 Dec 2009)
<p id="p-0001" num="0000">A method of creating a bioadhesive in a substantially aqueous environment is disclosed. The method includes the steps of placing an anionicially polymerized block copolymer containing an amide, which is prepared by reacting a difunctional anionic initiator with a sterically hindered ester of methacrylic acid (SEMA), into a solvent to allow the solvent to swell the block copolymer; reacting the anionically polymerized hindered ester of methacrylic acid with methacrylic acid (MMA); hydrolyzing the anionically polymerized block copolymer with an aqueous solution to afford a methyl methacrylate-methacrylic acid-methyl methacrylate block copolymer (MMA-MAA-MMA); reacting the MMA-MAA-MMA block copolymer with 3,4-dihydroxyphenyl alanine to afford an amide with the MAA portion of the block copolymer; and placing the solvent swollen block copolymer in water. The water is exchanged with the solvent to provide a bioadhesive in an aqueous environment.</p>
>> read more

ON WIRE LITHOGRAPHY-BASED MOLECULAR TRANSPORT JUNCTIONS (Fri, 27 Nov 2009)
On- wire lithography (OWL) fabricated nanogaps are used to construct molecular transport junctions (MTJs) through the assembly of molecular wires across a nanogap formed between two gold electrodes. Also disclosed are methods of characterizing a MTJ and optimizing gap size for two molecular wires of different dimensions.
>> read more

Organic light-emitting diodes and methods for assembly and enhanced charge injection (Fri, 20 Nov 2009)
<p id="p-0001" num="0000">New organic light-emitting diodes and related electroluminescent devices and methods for fabrication, using siloxane self-assembly techniques.</p>
>> read more

Method of using silicon molecular components for controlling charge migration and light emission of organic light-emitting diodes (Fri, 20 Nov 2009)
<p id="p-0001" num="0000">New organic light-emitting diodes and related electroluminescent devices and methods for fabrication, using siloxane self-assembly techniques.</p>
>> read more

Carbonyl-functionalized thiophene compounds and related device structures (Fri, 30 Oct 2009)
<p id="p-0001" num="0000">Carbonyl-functionalized oligo/polythiophene compounds, and related semiconductor components and related device structures.</p>
>> read more

Contrast agents (Fri, 30 Oct 2009)
<p id="p-0001" num="0000">The present invention relates generally to multimodal magnetic resonance imaging (MRI) contrast agents. In particular, the present invention provides a MRI contrast agent configured to manipulate both the longitudinal (T₁) and transverse (T₂) relaxation times of surrounding water proton spins.</p>
>> read more

Self-assembling peptide amphiphiles and related methods for growth factor delivery (Fri, 30 Oct 2009)
<p id="p-0001" num="0000">Amphiphilic peptide compounds comprising one or more epitope sequences for binding interaction with one or more corresponding growth factors, micellar assemblies of such compounds and related methods of use.</p>
>> read more

Catalytic enantioselective synthesis of flavanones and chromanones (Fri, 16 Oct 2009)
<p id="p-0001-en" num="0000">Various chromanone, flavanone and abyssinone compounds as can be prepared enantioselectively using a chiral thiourea catalyst.</p>
>> read more

Modified Acrylic Block Copolymers For Hydrogels and Pressure Sensitive Wet Adhesives (Fri, 02 Oct 2009)
<p id="p-0001-en" num="0000">A method of producing an acrylic block copolymer comprising hydrophobic poly (lower alkyl methoacrylate), hydrophilic poly (lower alkyl methacrylic acid), and hydrophobic poly (lower alkyl methacrylate).</p>
>> read more

Barriers for facilitating biological reactions (Fri, 02 Oct 2009)
<p id="p-0001" num="0000">The present invention relates to systems, devices, and methods for performing biological reactions. In particular, the present invention relates to the use of lipophilic, water immiscible, or hydrophobic barriers in sample separation, purification, modification, and analysis processes.</p>
>> read more

Modified Acrylic Block Copolymers For Hydrogels and Pressure Sensitive Wet Adhesives (Fri, 25 Sep 2009)
<p id="p-0001-en" num="0000">A method of producing an acrylic block copolymer comprising hydrophobic poly (lower alkyl methoacrylate), hydrophilic poly (lower alkyl methacrylic acid), and hydrophobic poly (lower alkyl methacrylate).</p>
>> read more

BARRIERS FOR FACILITATING BIOLOGICAL REACTIONS (Sat, 12 Sep 2009)
The present invention relates to systems, devices, and methods for performing biological reactions. In particular, the present invention relates to the use of lipophilic, water immiscible, or hydrophobic barriers in sample separation, purification, modification, and analysis processes.
>> read more

Organic light-emitting diodes and methods for assembly and enhanced charge injection (Fri, 11 Sep 2009)
<p id="p-0001" num="0000">New organic light-emitting diodes and related electroluminescent devices and methods for fabrication, using siloxane self-assembly techniques.</p>
>> read more

Gas adsorption and gas mixture separations using carborane-based MOF material (Fri, 04 Sep 2009)
<p id="p-0001-en" num="0000">A method of separating a mixture of carbon dioxide and a hydrocarbon gas using a metal-organic framework (MOF) material having a three-dimensional carborane ligand structure.</p>
>> read more

CATALYTIC ENANTIOSELECTIVE SYNTHESIS OF FLAVANONES AND CHROMANES (Fri, 04 Sep 2009)
Various chromanone, flavanone and abyssinone compounds as can be prepares enantioselectively using a chiral thiourea catalyst.
>> read more

AMORPHOUS INFINITE COORDINATION POLYMER MICROPARTICLES AND USE FOR HYDROGEN STORAGE (Fri, 28 Aug 2009)
<p id="p-0001-en" num="0000">Infinite coordination polymeric (ICP) materials are disclosed. One ICP material has a formula</p> <p id="p-0002-en" num="0000"> <chemistry id="chem-us-00001-en" num="00001"> <img id="emi-c00001" he="18.37mm" wi="60.28mm" file="us20090211445a1-20090827-c00001.tif" img-content="chem" img-format="tif"/> </chemistry> </p> <p id="p-0003-en" num="0000">wherein —O(CO)-L-C(O)O— is the ligand, M and M′ are each a metal ion and are the same or different, Sol and Sol′ are each a solvent molecule and are the same or different, x and y are each selected from the group consisting of 0, 0.5, 1, 1.5, 2, 2.5, 3, and 3.5, and n is at least 100. Also disclosed are methods of making the ICP materials and methods of adsorbing a substance by contacting the ICP material with the substance. The substance can be a gas. Further disclosed is a crystalline metallo-ligand complex having a structure</p> <p id="p-0004-en" num="0000"> <chemistry id="chem-us-00002-en" num="00002"> <img id="emi-c00002" he="68.58mm" wi="73.15mm" file="us20090211445a1-20090827-c00002.tif" img-content="chem" img-format="tif"/> </chemistry> </p>
>> read more

MRI CONTRAST AGENTS AND RELATED METHODS OF USE (Fri, 07 Aug 2009)
<p id="p-0001-en" num="0000">The present invention relates to contrast agents for MRI and related methods of use.</p>
>> read more

Compositions and treatments using pyridazine compounds and cholinesterase inhibitors (Fri, 07 Aug 2009)
<p id="p-0001" num="0000">The invention relates to compositions, conjugates and methods comprising pyridazine compounds and cholinesterase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.</p>
>> read more

ANTI-CANCER COMPOUNDS (Fri, 17 Jul 2009)
The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation.
>> read more

Self-assembly and mineralization of peptide-amphiphile nanofibers (Fri, 19 Jun 2009)
<p id="p-0001-en" num="0000">Peptide-amphiphilic compositions capable of self-assembly into useful nanostructures.</p>
>> read more

Universal phosphoramidite for preparation of modified biomolecules and surfaces (Fri, 22 May 2009)
<p id="p-0001-en" num="0000">Reagents useful for attaching biomolecules (e.g., proteins, oligonucleotides, and other biomolecules) to a surface, processes of attaching molecules to a surface to form modified surfaces using these reagents, and methods of detecting a target compound using these modified surfaces are disclosed.</p>
>> read more

INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS (Fri, 15 May 2009)
<p id="p-0001-en" num="0000">The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4.</p>
>> read more

Substrate-independent layer-by-layer assembly using catechol-functionalized polymers (Fri, 15 May 2009)
<p id="p-0001" num="0000">The present invention provides a simple, non-destructive and versatile method that enables layer-by-layer (LbL) assembly to be performed on virtually any substrate. A catechol-functionalized polymer which adsorbs to virtually all surfaces and can serve as a platform for LbL assembly in a surface-independent fashion is also provided.</p>
>> read more

SUBSTRATE-INDEPENDENT LAYER-BY-LAYER ASSEMBLY USING CATECHOL-FUNCTIONALIZED POLYMERS (Fri, 15 May 2009)
The present invention provides a simple, non-destructive and versatile method that enables layer-by-layer (LbL) assembly to be performed on virtually any substrate. A novel catechol-functionalized polymer which adsorbs to virtually all surfaces and can serve as a platform for LbL assembly in a surface-independent fashion is also provided.
>> read more

Anti-Antiogenic Fragments of Pigment Epithelium-Derived Factor (PEDF) (Fri, 08 May 2009)
<p id="p-0001-en" num="0000">The present invention provides anti-angiogenic derived from pigment epithelium-derived factor (PEDF) pharmaceutical compositions comprising the peptides, and methods of preventing angiogenesis. Such methods are useful in treating angiogenesis-associated disorders and diseases.</p>
>> read more

Heteroaromatic selective inhibitors of neuronal nitric oxide synthase (Fri, 24 Apr 2009)
<p id="p-0001" num="0000">Compounds selectively inhibiting neuronal nitric oxide synthase (nNos), such compounds of a formula</p> <p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"> <img id="EMI-C00001" he="24.30mm" wi="49.28mm" file="US08158658-20120417-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/> </chemistry> <br/> wherein the variables are defined, herein. </p>
>> read more

INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS (Fri, 17 Apr 2009)
The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4.
>> read more

SCREENING FOR MODULATORS OF METALATION PATHWAYS FOR METALLOPROTEINS (Fri, 20 Mar 2009)
<p id="p-0001-en" num="0000">The present invention is directed to compositions and methods for screening of metalation pathways for the metalation of metalloproteins.</p>
>> read more

CONTRAST AGENTS (Fri, 20 Mar 2009)
The present invention relates generally to multimodal magnetic resonance imaging (MRI) contrast agents. In particular, the present invention provides a MRI contrast agent configured to manipulate both the longitudinal (T1) and transverse (T2) relaxation times of surrounding water proton spins.
>> read more

Hole transport layer compositions and related diode devices (Fri, 06 Mar 2009)
<p id="p-0001" num="0000">Hole transport layer compositions comprising a silylated aryl amine and a polymeric component, to enhance performance of an associated electroluminescent device.</p>
>> read more

Compositions and methods for magnetic resonance imaging contrast agents (Fri, 27 Feb 2009)
<p id="p-0001" num="0000">The present application provides for compositions and methods of creating and applying contrast agents that find use in magnetic resonance imaging (MRI). In particular, contrast agents that comprise monodisperse, protein polymer backbones capable of chelating multiple paramagnetic ions resulting in high relaxivity for use in enhancing MRI signal intensity.</p>
>> read more

Conjugated monomers and polymers and preparation and use thereof (Fri, 06 Feb 2009)
<p id="p-0001" num="0000">Disclosed are new conjugated compounds (e.g., monomers and polymers) that include ladder-type moieties which can be used for preparing semiconducting materials. Such conjugated compounds can exhibit high n-type carrier mobility and/or good current modulation characteristics. Compounds of the present teachings also can exhibit ambipolar semiconducting activity. In addition, the compounds of the present teachings can possess certain processing advantages such as solution-processability and/or good stability in ambient conditions.</p>
>> read more

CONJUGATED MONOMERS AND POLYMERS AND PREPARATION AND USE THEREOF (Fri, 06 Feb 2009)
Disclosed are new conjugated compounds (e.g., monomers and polymers) that include ladder-type moieties which can be used for preparing semiconducting materials. Such conjugated compounds can exhibit high n-type carrier mobility and/or good current modulation characteristics. Compounds of the present teachings also can exhibit ambipolar semiconducting activity. In addition, the compounds of the present teachings can possess certain processing advantages such as solution- processability and/or good stability in ambient conditions.
>> read more

Metal-organic framework materials based on icosahedral boranes and carboranes (Fri, 30 Jan 2009)
<p id="p-0001-en" num="0000">Disclosed herein are metal-organic frameworks of metals and boron rich ligands, such as carboranes and icosahedral boranes. Methods of synthesizing and using these materials in gas uptake are disclosed.</p>
>> read more

Pyridazine compounds and methods (Fri, 30 Jan 2009)
<p id="p-0001" num="0000">The invention relates to novel chemical compounds of Formula I</p> <p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"> <img id="EMI-C00001" he="38.27mm" wi="69.85mm" file="US08063047-20111122-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/> </chemistry> <br/> compositions and methods of using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications. </p>
>> read more

Sparsely cross-linked nanogels: a novel polymer structure for microchannel DNA sequencing (Fri, 09 Jan 2009)
<p id="p-0001-en" num="0000">The present invention is generally directed to novel polymeric materials for use in the electrophoretic separation of nucleic acids. In particular, the novel polymer materials are sparsely crosslinked nanogels, dissolved in an aqueous buffer to form solutions with moderate to high viscosity. The present invention further provides methods for generating such novel polymers, and related methods of their use.</p>
>> read more

Selective neuronal nitric oxide synthase inhibitors (Wed, 31 Dec 2008)
<p id="p-0001-en" num="0000">Peptidomimetic compositions for selective inhibition of neuronal nitric oxide synthase.</p>
>> read more

COMPOSITIONS AND METHODS FOR POLYMER-CAGED LIPOSOMES (Fri, 26 Dec 2008)
<p id="p-0001-en" num="0000">The present invention provides liposomal compositions and methods of using such compositions in vitro and in vivo. In particular, the present invention provides stable, polymer-caged liposomes comprising a pH responsive delivery mechanism for delivery of nucleic acids, peptides, small molecules, drugs, etc. in vitro and in vivo.</p>
>> read more

Pyridazine compounds, compositions and methods (Fri, 26 Dec 2008)
<p id="p-0001" num="0000">The invention relates to novel chemical compounds and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.</p>
>> read more

Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay (Fri, 19 Dec 2008)
<p id="p-0001-en" num="0000">Disclosed herein are methods of screening sequence selectivity of oligonucleotide-binding molecules using a gold nanoparticle based colorimetric assay.</p>
>> read more

COMPOSITIONS AND METHODS FOR POLYMER-CAGED LIPOSOMES (Fri, 19 Dec 2008)
The present invention provides liposomal compositions and methods of using such compositions in vitro and in vivo. In particular, the present invention provides stable, polymer-caged liposomes comprising a pH responsive delivery mechanism for delivery of nucleic acids, peptides, small molecules, drugs, etc. in vitro and in vivo.
>> read more

n-Type thiophene semiconductors (Fri, 28 Nov 2008)
<p id="p-0001-en" num="0000">The new fluorocarbon-functionalized and/or heterocycle-modified polythiophenes, in particular, α,ω-diperfluorohexylsexithiophene DFH-6T can be straightforwardly prepared in high yield and purity. Introduction of such modifications to a thiophene core affords enhanced thermal stability and volatility, and increased electron affinity versus the unmodified compositions of the prior art. Evaporated films behave as n-type semiconductors, and can be used to fabricate thin film transistors with FET mobilities ˜0.01 cm²/Vs—some of the highest reported to date for n-type organic semiconductors.</p> <p id="p-0002-en" num="0000"> <chemistry id="chem-us-00001-en" num="00001"> <img id="emi-c00001" he="11.26mm" wi="74.08mm" file="US07842198-20101130-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/> </chemistry> </p>
>> read more

HIGH ENERGY DENSITY NANOCOMPOSITES AND RELATED METHODS OF PREPARATION (Fri, 21 Nov 2008)
Metal oxide-polymer composites and methods of preparation.
>> read more

MACROMONOMERS AND HYDROGEL SYSTEMS USING NATIVE CHEMICAL LIGATION, AND THEIR METHODS OF PREPARATION (Fri, 31 Oct 2008)
The present invention provides novel biocompatible macromonomers, hydrogels, methods of synthesis and methods of use thereof. The biocompatible hydrogels of the present invention are prepared using native chemical ligation (NCL), in which a thioester readily reacts with a N-terminal thiol (cysteine) through transesterification and rearrangement to form an amide bond through a five-member ring intermediate.
>> read more

DOPA-FUNCTIONALIZED, BRANCHED, POLY(AKLYLENE OXIDE) ADHESIVES (Fri, 10 Oct 2008)
<p id="p-0001-en" num="0000">The invention describes DOPA functionalized, branched, polyalkylene oxide materials that are useful as adhesives.</p>
>> read more

COMPOSITIONS COMPRISING DERIVATIVES OF 3 -PHENYLPYRIDAZINE FOR TREATING SEIZURE-RELATED DISORDERS (Sat, 13 Sep 2008)
The present invention relates to therapeutic and/or prophylactic uses of pyridazine compounds and to pharmaceutical compositions containing one or more of these compounds as an active component for treating a disorder characterized by conduction disturbances, electroconvulsions and/or seizures, in particular epilepsy, more particularly pediatric epilepsy. In an aspect of the invention, the pyridazine compound has the Formula (Ia) or (Ib) wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the description.
>> read more

INHIBITORS OF THE MEVALONATE PATHWAY OF STREPTOCOCCUS PNEUMONIAE (Sat, 13 Sep 2008)
Compounds and related methods as can be used for selective mevalonate pathway inhibitors.
>> read more

Allosterically catalyzed signal amplification in chemical and biological sensing (Fri, 05 Sep 2008)
<p id="p-0001-en" num="0000">Coordination complexes having at least two structural conformations are disclosed. The coordination complexes contain at least one metal center and at least one hemi-labile ligand, and change structural conformations due to the presence or absence of allosteric effectors. Methods of detecting an analyte using the coordination complexes are also disclosed.</p>
>> read more

Compounds and related methods for mutant p53 reactivation (Fri, 29 Aug 2008)
<p id="p-0001-en" num="0000">Ketoamine compounds and related methods for reactivation of tumor suppressor protein p53.</p>
>> read more

Acene-based organic semiconductor materials and methods of preparing and using the same (Fri, 08 Aug 2008)
<p id="p-0001" num="0000">Acene-based compounds that can be used to prepare n-type semiconductor materials are provided with processes for preparing the same. Composites and electronic devices including n-type semiconductor materials prepared from these compounds also are provided.</p>
>> read more

BIOMIMETIC MODULAR ADHESIVE COMPLEX: MATERIAL, METHODS AND APPLICATIONS THEREFORE (Fri, 01 Aug 2008)
Nano-scale or micro-scale adhesive structures comprising an array of nano-fabricated, pillars, the pillars having coated upon, or having disposed on a working surface thereof, a protein- mimetic, marine-adhesive coating. Methods of fabricating the nano-scale pillars, synthesis of the protein-mimetic coating or wet adhesive and application of the adhesive to the pillars are described.
>> read more

Self-assembly of peptide-amphiphile nanofibers under physiological conditions (Fri, 25 Jul 2008)
<p id="p-0001-en" num="0000">Peptide amphiphile compounds, compositions and methods for self-assembly or nanofibrous network formation under neutral or physiological conditions.</p>
>> read more

FOULING RESISTANT COATINGS AND METHODS OF MAKING SAME (Fri, 25 Jul 2008)
The invention provides surface treatments that reduce or eliminate marine bio fouling of various surfaces. A surface that is to be subjected to a marine environment can be treated with a mPEG-DOPA. The treated surface is thus rendered less susceptible to fouling of the surface.
>> read more

High energy density nanocomposites and related methods of preparation (Fri, 11 Jul 2008)
<p id="p-0001" num="0000">Disclosed are metal oxide-polymer composites having a substrate comprising a metal oxide component, an aluminum oxide component, and a metallocene olefin polymerization catalyst component coupled to the substrate. The compositions can be used as thin films in an insulator device. Also disclosed is a method of preparing such compositions.</p>
>> read more

Surface-Independent, Surface-Modifying, Multifunctional Coatings and Applications Thereof (Fri, 27 Jun 2008)
<p id="p-0001-en" num="0000">The present invention provides a surface-independent surface-modifying multifunctional biocoating and methods of application thereof. The method comprises contacting at least a portion of a substrate with an alkaline solution comprising a surface-modifying agent (SMA) such as dopamine so as to modify the substrate surface to include at least one reactive moiety. In another version of the invention, a secondary reactive moiety is applied to the SMA-treated substrate to yield a surface-modified substrate having a specific functionality.</p>
>> read more

COMPOSITIONS AND METHODS FOR MAGNETIC RESONANCE IMAGING CONTRAST AGENTS (Fri, 20 Jun 2008)
The present application provides for compositions and methods of creating and applying contrast agents that find use in magnetic resonance imaging (MRI). In particular, contrast agents that comprise monodisperse, protein polymer backbones capable of chelating multiple paramagnetic ions resulting in high relaxivity for use in enhancing MRI signal intensity.
>> read more

Compounds and related methods for inhibition of gamma-aminobutyric acid aminotransferase (Wed, 04 Jun 2008)
<p id="p-0001-en" num="0000">(1S, 3S)-3-Amino-4-difluoromethylene-1-cyclopentanoic acid illustrates a novel class of compounds as potent irreversible inhibitors of γ-aminobutyric acid aminotransferase (GABA-AT). The corresponding monofluoro-substituted compounds also are potent time-dependent inhibitors of GABA-AT.</p>
>> read more

ACENE-BASED ORGANIC SEMICONDUCTOR MATERIALS AND METHODS OF PREPARING AND USING THE SAME (Fri, 30 May 2008)
Acene-based compounds that can be used to prepare n-type semiconductor materials are provided with processes for preparing the same. Composites and electronic devices including n-type semiconductor materials prepared from these compounds also are provided.
>> read more

MRI method for quantification of cerebral perfusion (Fri, 23 May 2008)
<p id="p-0001" num="0000">A method for calculating quantitative perfusion measurements using an MRI system includes a pulse sequence that acquires perfusion weighted images and additionally measures T₁values before and after the administration of a contrast agent. T₁values are measured by rapidly sampling a longitudinal relaxation curve and employed to determine the blood volume in tissue. A correction factor for the effect of water diffusion between blood vessels and the extravascular space is determined.</p>
>> read more

Cellular Arrays (Fri, 09 May 2008)
<p id="p-0001-en" num="0000">The present invention relates to characterizing transcription within cells. In particular, the present invention provides transfected cell arrays (e.g., two-dimensional and/or three-dimensional arrays) and systems, kits and methods utilizing the same (e.g., for transcriptional activity characterization). Compositions and methods of the present invention find use in, among other things, research, drug discovery and clinical (e.g., diagnostic, preventative and therapeutic) applications.</p>
>> read more

Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase (Fri, 09 May 2008)
<p id="p-0001" num="0000">Peptidomimetic compounds as can inhibit neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as but not limited to stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease.</p>
>> read more

ORGANIC SEMICONDUCTOR MATERIALS AND METHODS OF PREPARING AND USE THEREOF (Sat, 03 May 2008)
Solution-processable organic n-type semiconductor materials are provided with processes for preparing the same. Composites and electronic devices including the organic n-type semiconductor materials also are provided.
>> read more

SURFACE-INDEPENDENT, SURFACE-MODIFYING, MULTIFUNCTIONAL COATINGS AND APPLICATIONS THEREOF (Fri, 25 Apr 2008)
The present invention provides a surface-independent surface-modifying multifunctional biocoating and methods of application thereof. The method comprises contacting at least a portion of a substrate with an alkaline solution comprising a surface-modifying agent (SMA) such as dopamine so as to modify the substrate surface to include at least one reactive moiety. In another version of the invention, a secondary reactive moiety is applied to the SMA-treated substrate to yield a surface-modified substrate having a specific functionality.
>> read more

POTENT AND HIGHLY SELECTIVE HETEROAROMATIC INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE (Fri, 11 Apr 2008)
Peptidomimetic compounds as can inhibit neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as but not limited to stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease.
>> read more

Compositions and methods for the treatment and prevention of cancer (Wed, 27 Feb 2008)
<p id="p-0001-en" num="0000">The present invention relates to new classes of anti-cancer agents. In particular, the present invention provides materials derived from natural sources as anti-cancer agents, alone, or in combination with other anti-cancer agents or therapies.</p>
>> read more

Transparent conducting oxide thin films and related devices (Fri, 01 Feb 2008)
<p id="p-0001" num="0000">Transparent conducting oxide thin films having a reduced indium content and/or an increased tin content are provided. In addition, processes for producing the same, precursors for producing the same, and transparent electroconductive substrate for display panels and organic electroluminescence devices, both including the transparent conducting oxide thin films, are provided.</p>
>> read more

Myosin light chain kinase inhibitor compounds, compostions and related methods of use (Fri, 25 Jan 2008)
<p id="p-0001-en" num="0000">Pyridazinyl compounds, compositions and related methods of use.</p>
>> read more

Naphthalene-based semiconductor materials and methods of preparing and use thereof (Fri, 25 Jan 2008)
<p id="p-0001-en" num="0000">Provided are mono- and diimide naphthalene compounds for use in the fabrication of various device structures. In some embodiments, the naphthalene core of these compounds are mono-, di-, or tetra-substituted with cyano group(s) or other electron-withdrawing substituents or moieties. Such mono- and diimide naphthalene compounds also can be optionally N-substituted.</p>
>> read more

MYOSIN LIGHT CHAIN KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND RELATED METHODS OF USE (Fri, 25 Jan 2008)
Pyridazinyl compounds, compositions and related methods of use.
>> read more

CROSSLINKED POLYMERIC DIELECTRIC MATERIALS AND METHODS OF MANUFACTURING AND USE THEREOF (Fri, 04 Jan 2008)
Solution-processable dielectric materials are provided, along with precursor compositions and processes for preparing the same. Composites and electronic devices including the dielectric materials also are provided.
>> read more

NAPHTHALENE-BASED SEMICONDUCTOR MATERIALS AND METHODS OF PREPARING AND USE THEREOF (Sat, 22 Dec 2007)
Provided are mono- and diimide naphthalene compounds for use in the fabrication of various device structures. In some embodiments, the naphthalene core of these compounds are mono-, di-, or tetra-substituted with cyano group(s) or other electron-withdrawing substituents or moieties. Such mono- and diimide naphthalene compounds also can be optionally N-substituted.
>> read more

Silole-based polymers and semiconductor materials prepared from the same (Fri, 07 Dec 2007)
<p id="p-0001-en" num="0000">The present teachings provide silole-based polymers that can be used as p-type semiconductors. More specifically, the present teachings provide polymers that include a repeating unit of Formula I:</p> <p id="p-0002-en" num="0000"> <chemistry id="chem-us-00001-en" num="00001"> <img id="emi-c00001-en" he="36.41mm" wi="69.68mm" file="US07605225-20091020-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/> </chemistry> wherein R¹, R², R³, R⁴, R⁵, R⁶, Z, x, and x′ are as defined herein. The present teachings also provide methods of preparing these polymers, and relate to various compositions, composites, and devices that incorporate these polymers. </p>
>> read more

SILOLE-BASED POLYMERS AND SEMICONDUCTOR MATERIALS PREPARED FROM THE SAME (Fri, 23 Nov 2007)
The present teachings provide silole-based polymers that can be used as p-type semiconductors. More specifically, the present teachings provide polymers that include a repeating unit of Formula I: wherein R1, R2, R3, R4, R5, R6, Z, x, and x1 are as defined herein. The present teachings also provide methods of preparing these polymers, and relate to various compositions, composites, and devices that incorporate these polymers.
>> read more

COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND SECRETASES (Fri, 16 Nov 2007)
The invention relates to compositions, conjugates and methods comprising pyridazine compounds and secretase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.
>> read more

PYRIDAZINES FOR DEMYELINATING DISEASES AND NEUROPATHIC PAIN (Fri, 09 Nov 2007)
The invention relates to compositions and methods for treating patients with Demyelinating Diseases and Conditions including Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compositions and methods may also be used for Stroke Rehabilitation and the treatment of pain disorders including Neuropathic Pain and Chemokine-Induced Pain. The compositions comprise one or more pyridazine compounds having a pyridazinyl radical pendant with an aryl or substituted aryl, a heteroaryl or substituted heteroaryl.
>> read more

COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS (Fri, 09 Nov 2007)
The invention relates to compositions, conjugates and methods comprising pyridazine compounds and cholinesterase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.
>> read more

FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES (Fri, 09 Nov 2007)
The invention relates to chemical compounds, compositions and methods of making and using the same. In particular, the invention provides selected pyridazine compounds of the formula (I) are independently hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, sulfate, sulfenyl, sulfinyl, sulfonyl, sulfonate, sulfoxide, silyl, silyloxy, silylalkyl, silylthio, =0, =S, phosphonate, ureido, carboxyl, carbonyl, carbamoyl, or carboxamide; and X is optionally substituted pyrimidinyl or pyridazinyl, an isomer, a pharmaceutically acceptable salt, or derivative thereof. The invention additional relates to compositions comprising the compounds, and methods of using the compounds and compositions for modulation of cellular pathways, for treatment or prevention of inflammatory diseases, for research, drug screening, and therapeutic applications.
>> read more

Nanomolar β-lactamase inhibitors (Wed, 19 Sep 2007)
<p id="p-0001-en" num="0000">New carboxyphenyl-glycylboronic acid transition-state analog inhibitors, representative of a class of compounds effective against class C β-lactamase AmpC. The new compounds improve inhibition by over two-orders of magnitude compared to analogous glycylboronic acids, with Ki values as low as 1 nM.</p>
>> read more

Solid phase host compositions (Wed, 19 Sep 2007)
<p id="p-0001-en" num="0000">A new family of silicon-based polymers has been prepared in which organic host components are bound covalently. The polymer is a polysilsesquioxane matrix comprising, for example, hosts such as cyclodextrins (CD) or calixarenes (CX).</p>
>> read more

Zinc-chelating ratiometric fluorescent probes and related methods (Wed, 29 Aug 2007)
<p id="p-0001-en" num="0000">Benzoxazole fluorescent sensor compounds and related ratiometric imaging methods for zinc metal ion.</p>
>> read more

Organic light-emitting diodes and methods for assembly and emission control (Fri, 27 Jul 2007)
<p id="p-0001-en" num="0000">New organic light-emitting diodes and related electroluminescent devices and methods for fabrication, using siloxane self-assembly techniques. </p>
>> read more

CHEMICALLY TAILORABLE NANOPARTICLES REALIZED THROUGH METAL-METALLOLIGAND COORDINATION CHEMISTRY (Fri, 11 May 2007)
Colloidal particles of infinite coordination polymers are disclosed. Also disclosed are methods of synthesizing the colloidal particles and methods of detecting biological and chemical analytes using, the colloidal particles.
>> read more

CARBONYL-FUNCTIONALIZED THIOPHENE COMPOUNDS AND RELATED DEVICE STRUCTURES (Fri, 04 May 2007)
Carbonyl-functionalized oligo/polythiophene compounds, and related semiconductor components and related device structures.
>> read more

VIGABATRIN BIOISOTERES AND RELATED METHODS OF USE (Fri, 30 Mar 2007)
Compounds bioisoteric to vigabatrin and related methods of use.
>> read more

ALLOSTERICALLY CATALYZED SIGNAL AMPLIFICATION IN CHEMICAL AND BIOLOGICAL SENSING (Fri, 16 Feb 2007)
Coordination complexes having at least two structural conformations are disclosed. The coordination complexes contain at least one metal center and at least one hemi-labile ligand, and change structural conformations due to thepresence or absence of allosteric effectors. Methods of detecting an analyte using the coordination complexes are also disclosed.
>> read more

Twisted π-electron system chromophore compounds with very large molecular hyperpolarizabilities and related compositions and devices (Fri, 27 Oct 2006)
<p id="p-0001-en" num="0000">Unconventional twisted π-electron system electro-optic (EO) chromophores/compounds, compositions and related device structures. Crystallographic analysis of several non-limiting chromophores reveals, for instance, large ring-ring dihedral twist angles and a highly charge-separated zwitterionic structure in the ground state, in both solution phase and solid-state.</p>
>> read more

Peptidomimetic polymers for antifouling surfaces (Fri, 27 Oct 2006)
<p id="p-0001-en" num="0000">Peptidomimetic polymers comprising one or more DOPA moieties and related coatings and composites.</p>
>> read more

TWISTED π-ELECTRON SYSTEM CHROMOPHORE COMPOUNDS WITH VERY LARGE MOLECULAR HYPERPOLARIZABILITIES AND RELATED COMPOSITIONS AND DEVICES (Fri, 29 Sep 2006)
Unconventional twisted π-electron system electro-optic (EO) chromophores/compounds, compositions and related device structures. Crystallographic analysis of several non-limiting chromophores reveals, for instance, large ring-ring dihedral twist angles and a highly charge-separated zwitterionic structure in the ground state, in both solution phase and solid-state.
>> read more

Zinc-chelating ratiometric fluorescent probes and related methods (Wed, 13 Sep 2006)
<p id="p-0001-en" num="0000">Benzoxazole fluorescent sensor compounds and related ratiometric imaging methods for zinc metal ion.</p>
>> read more

COMPOSITIONS AND METHODS FOR ANALYTE DETECTION (Sat, 09 Sep 2006)
The invention relates to novel methods and compositions for the detection of analytes using the nuclear reorganization energy, λ, of an electron transfer process. In particular, the present invention provides probes of the outer-sphere environment of a redox center and methods of correlating changes in electrochemical properties to characterize the same.
>> read more

POLYMERIC COMPOSITIONS AND RELATED METHODS OF USE (Fri, 01 Sep 2006)
Methods for surface-initiated atom transfer radical polymerization, which can utilize a catecholic alkyl halide initiator.
>> read more

Carbonyl-functionalized thiophene compounds and related device structures (Fri, 25 Aug 2006)
<p id="p-0001-en" num="0000">Carbonyl-functionalized oligo/polythiophene compounds, and related semiconductor components and related device structures.</p>
>> read more

METHODS AND COMPOSITIONS FOR ENCAPSULATION OF CELLS (Fri, 28 Jul 2006)
The present invention relates to methods and compositions for altering (e.g., augmenting or stimulating) differentiation and growth of cells (e.g., neural progenitor cells and neurons). In particular, the present invention relates to compositions comprising one or more self-assembling peptide amphiphiles (e.g., in solution or that generate (e.g., self-assemble into) nanofibers (e.g., that are able to encapsulate cells and promote cellular differentiation (e.g., neurite development))) and methods of using the same. Compositions and methods of the present invention find use in research, clinical (e.g., therapeutic) and diagnostic settings.
>> read more

n-Type thiophene semiconductors (Fri, 16 Jun 2006)
<p id="p-0001-en" num="0000">The new fluorocarbon-functionalized and/or heterocycle-modified polythiophenes, in particular, α,ω-diperfluorohexylsexithiophene DFH-6T can be straightforwardly prepared in high yield and purity. Introduction of such modifications to a thiophene core affords enhanced thermal stability and volatility, and increased electron affinity versus the unmodified compositions of the prior art. Evaporated films behave as n-type semiconductors, and can be used to fabricate thin film transistors with FET mobilities ˜0.01 cm²/Vs—some of the highest reported to date for n-type organic semiconductors</p> <p id="p-0002-en" num="0000"> <chemistry id="chem-us-00001-en" num="00001"> <img id="emi-c00001" he="11.43mm" wi="75.52mm" file="US07374702-20080520-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/> </chemistry> </p>
>> read more

PYRIDAZINE COMPOUNDS AND METHODS (Fri, 12 May 2006)
The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.
>> read more

PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS (Fri, 12 May 2006)
The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of making and using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.
>> read more

Self-immolative magnetic resonance imaging contrast agents sensitive to beta-glucuronidase (Fri, 28 Apr 2006)
<p id="p-0001-en" num="0000">The present invention relates to magnetic resonance imaging (MRI) contrast agent. In particular, the present invention provides MRI contrast agents that are sensitive to the enzyme beta-glucoronidase. The MRI contrast agents provide compositions and methods for non-invasive diagnostic imaging of tissues, including necrotic tumors. </p>
>> read more

Layer by layer self-assembly of large response molecular electro-optic materials by a desilylation strategy (Fri, 28 Apr 2006)
<p id="p-0001-en" num="0000">The preparation of robust, thin film materials with large second-order optical nonlinearities through the covalent self-assembly of chromophoric compositions and innovative use of silyl chemistry.</p>
>> read more

Sparsely cross-linked nanogels: a novel polymer structure for microchannel DNA sequencing (Fri, 07 Apr 2006)
<p id="p-0001-en" num="0000">The present invention is generally directed to novel polymeric mateirals for use in the electrophoretic separation of nucleic acids. In particular, the novel polymer materials are sparsely crosslinked nanogels, dissolved in an aqueous buffer to form solutions with moderate to high viscosity. The present invention further provides methods for generating such novel polymers, and related methods of their use.</p>
>> read more

Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death (Fri, 07 Apr 2006)
<p id="p-0001" num="0000">A novel class of pyridazine compositions and related methods of use.</p>
>> read more

ORGANIC LIGHT-EMITTING DIODES AND RELATED HOLE TRANSPORT COMPOUNDS (Fri, 03 Mar 2006)
New organic light-emitting diodes and related hole transport compounds and methods for fabrication, using siloxane self-assembly techniques.
>> read more

Polymeric compositions and related methods of use (Fri, 13 Jan 2006)
<p id="p-0001-en" num="0000">Methods for surface-initiated atom transfer radical polymerization, which can utilize a catecholic alkyl halide initiator.</p>
>> read more

POLYMERIC COMPOSITIONS AND RELATED METHODS OF USE (Fri, 16 Dec 2005)
Adhesive polymeric compositions which can comprise dihydroxyphenyl moieties and derivatives thereof, and related methods of use.
>> read more

SELF-IMMOLATIVE MAGNETIC RESONANCE IMAGING CONTRAST AGENTS SENSITIVE TO BETA-GLUCURONIDASE (Fri, 09 Dec 2005)
The present invention relates to magnetic resonance imaging (MRI) contrast agent. In particular, the present invention provides MRI contrast agents that are sensitive to the enzyme beta-glucoronidase. The MRI contrast agents provide compositions and methods for non-invasive diagnostic imaging of tissues, including necrotic tumors.
>> read more

REVERSIBLE AND CHEMICALLY PROGRAMMABLE MICELLE ASSEMBLY WITH DNA BLOCK-COPOLYMER AMPHIPHILES (Fri, 18 Nov 2005)
The present invention is directed to amphiphilic block copolymers. More particularly, the present invention is directed to amphiphilic block copolymers comprising a polynucleotide block and a hydrophobic polymer block, to micelles formed from the block copolymers, and to methods of using the micelles.
>> read more

Compounds and related methods for mutant p53 reactivation (Fri, 04 Nov 2005)
<p id="p-0001-en" num="0000">Ketoamine compounds and related methods for reactivation of tumor suppressor protein p53.</p>
>> read more

Organic light-emitting diodes and related hole transport compounds (Fri, 21 Oct 2005)
<p id="p-0001-en" num="0000">New organic light-emitting diodes and related hole transport compounds and methods for fabrication, using siloxane self-assembly techniques.</p>
>> read more

Oligo(p-phenylene vinylene) amphiphiles and methods for self-assembly (Fri, 30 Sep 2005)
<p id="p-0001-en" num="0000">Amphiphilic oligo(p-phenylene vinylene) compounds and methods of use en route to self-assembled composites and device fabrication.</p>
>> read more

Self-assembling peptide amphiphiles and related methods for growth factor delivery (Fri, 23 Sep 2005)
<p id="p-0001-en" num="0000">Amphiphilic peptide compounds comprising one or more epitope sequences for binding interaction with one or more corresponding growth factors, micellar assemblies of such compounds and related methods of use.</p>
>> read more

Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts (Fri, 23 Sep 2005)
<p id="p-0001-en" num="0000">A catalyst system useful to polymerize and co-polymerize polar and non-polar olefin monomers is formed by in situ reduction with a reducing agent of a catalyst precursor comprising{Cp*MRR′_n}⁺{A}⁻wherein Cp* is a cyclopentadienyl or substituted cyclopentadienyl moiety; M is an early transition metal; R is a C₁–C₂₀hydrocarbyl; R′ are independently selected from hydride, C₁–C₂₀hydrocarbyl, SiR″₃, NR″₂, OR″, SR″, GeR″₃, SnR″₃, and C═C-containing groups (R″=C₁–C₁₀hydrocarbyl); n is an integer selected to balance the oxidation state of M; and A is a suitable non-coordinating anionic cocatalyst or precursor. This catalyst system may form stereoregular olefin polymers including syndiotactic polymers of styrene and methylmethacrylate and isotactic copolymers of polar and nonpolar olefin monomers such as methylmethacrylate and styrene.</p>
>> read more

Polypeptoid pulmonary surfactants (Fri, 23 Sep 2005)
<p id="p-0001" num="0000">The present invention provides spreading agents based on sequence-specific oligomers comprising a peptoid, a peptide-peptoid chimera, a retropeptoid or a retro(peptoid-peptide) chimera, and methods for using the same, including for the treatment of respiratory distress of the lungs. The spreading agents are sequence-specific oligomers, including retrosequence-specific oligomers, based on a peptide backbone, that are designed as analogs of surfactant protein-B or surfactant protein-C.</p>
>> read more

PERYLENE n-TYPE SEMICONDUCTORS AND RELATED DEVICES (Fri, 26 Aug 2005)
Mono- and diimide perylene and naphthalene compounds, N- and core substituted with electron-withdrawing groups, for use in the fabrication of various device structures.
>> read more

Perylene n-type semiconductors and related devices (Fri, 12 Aug 2005)
<p id="p-0001-en" num="0000">Mono- and diimide perylene and naphthalene compounds, N- and core-substituted with electron-withdrawing groups, for use in the fabrication of various device structures.</p>
>> read more

SPARSELY CROSS-LINKED NANOGELS: A NOVEL POLYMER STRUCTURE FOR MICROCHANNEL DNA SEQUENCING (Fri, 05 Aug 2005)
The present invention is generally directed to novel polymeric material for use in the electrophoretic separation of nucleic acids. In particular, the novel polymer materials are sparsely crosslinked nanogels, dissolved in an aqueous buffer to form solutions with moderate to high viscosity. The present invention further provides methods for generating such novel polymers, and related methods of their use.
>> read more

Cyclic peptide antitumor agents (Fri, 22 Jul 2005)
<p id="p-0001-en" num="0000">Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.</p>
>> read more

Hole transport layer compositions and related diode devices (Fri, 08 Jul 2005)
<p id="p-0001-en" num="0000">Hole transport layer compositions comprising a silylated aryl amine and a polymeric component, to enhance performance of an associated electroluminescent device.</p>
>> read more

HOLE TRANSPORT LAYER COMPOSITIONS AND RELATED DIODE DEVICES (Fri, 08 Jul 2005)
Hole transport layer compositions comprising a silylated aryl amine and a polymeric component, to enhance performance of an associated electroluminescent device.
>> read more

OLIGO(P-PHENYLENE VINYLENE) AMPHIPHILES AND METHODS FOR SELF-ASSEMBLY (Fri, 24 Jun 2005)
Amphiphilic oligo(p-phenylene vinylene) compounds and methods of use en route to self-assembled composites and device fabrication.
>> read more

SELF-ASSEMBLING PEPTIDE AMPHIPHILES AND RELATED METHODS FOR GROWTH FACTOR DELIVERY (Fri, 24 Jun 2005)
Amphiphilic peptide compounds comprising one or more epitope sequences for binding interaction with one or more corresponding growth factors, micellar assemblies of such compounds and related methods of use.
>> read more

Vapor deposited electro-optic films self-assembled through hydrogen bonding (Fri, 17 Jun 2005)
<p id="p-0001-en" num="0000">The present invention introduces a novel route toward microstructural orientation into organic films, using multiple hydrogen-bonding to self-assemble chromophore molecules into electro-optic films in a net polar orientation. High-quality, thick films (up to micrometers) with molecular net dipole orientations can be fabricated under vacuum in hours. The film microstructure is intrinsically acentric; and the orientation is robust.</p>
>> read more

n-Type thiophene semiconductors (Fri, 03 Jun 2005)
<p id="p-0001-en" num="0000">The new fluorocarbon-functionalized and/or heterocycle-modified polythiophenes, in particular, α,ω-diperfluorohexylsexithiophene DFH-6T can be straightforwardly prepared in high yield and purity. Introduction of such modifications to a thiophene core affords enhanced thermal stability and volatility, and increased electron affinity versus the unmodified compositions of the prior art. Evaporated films behave as n-type semiconductors, and can be used to fabricate thin film transistors with FET mobilities ˜0.01 cm²Vs—some of the highest reported to date for n-type organic semiconductors. <chemistry id="chem-us-00001-en" num="00001"><img id="emi-c00001-en" he="11.26mm" wi="74.00mm" file="US06991749-20060131-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p>
>> read more

Heteroaromatic selective inhibitors of neuronal nitric oxide synthase (Fri, 20 May 2005)
<p id="p-0001-en" num="0000">Compounds inhibiting neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease, such compounds of a formula.</p> <p id="p-0002-en" num="0000"> <chemistry id="chem-us-00001-en" num="00001"> <img id="emi-c00001" he="23.20mm" wi="49.36mm" file="US07470790-20081230-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/> </chemistry> </p>
>> read more

COMPOUNDS AND RELATED METHODS FOR MUTANT p53 REACTIVATION (Fri, 13 May 2005)
Ketoamine compounds and related methods for reactivation of tumor suppressor protein p53.
>> read more

CYCLIC PEPTIDE ANTITUMOR AGENTS (Fri, 22 Apr 2005)
Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.
>> read more

HETEROAROMATIC SELECTIVE INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE (Fri, 25 Mar 2005)
Compounds inhibiting neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease, such compounds of a formula.
>> read more

Metal-ligand complexes and related methods of chemical CO2 fixation (Wed, 23 Mar 2005)
<p id="p-00001-en" num="00001">Salen complexes were found to be excellent catalysts for the reaction of terminal epoxides with CO₂when used in conjunction with a Lewis base cocatalyst (DMAP). This catalyst system cleanly affords the product cyclic carbonates in high yield under mild reaction conditions and is applicable to a variety of terminal epoxides.</p>
>> read more

Layer by layer self-assembly of large response molecular electro-optic materials by a desilylation strategy (Wed, 16 Feb 2005)
<p id="p-00001-en" num="00001">The preparation of robust, thin film materials with large second-order optical nonlinearities through the covalent self-assembly of chromophoric compositions and innovative use of silyl chemistry.</p>
>> read more

PER-6-AMINOSUBSTITUTED-DEOXY-CYCLODEXTRINS TO TREAT ALZHEIMER’S DISEASES (Fri, 11 Feb 2005)
Per-6-substituted-per-6-deoxy-cyclodex­trins and compositions containing the same are dis­closed. The compounds and compositions inhibit the formation and/or activity of soluble beta-amyloid-pep­tide derived oligomers, and can be used to treat diseases and conditions wherein such inhibition is beneficial, for example, Alzheimer's and related disease.
>> read more

Injectable and bioadhesive polymeric hydrogels as well as related methods of enzymatic preparation (Fri, 31 Dec 2004)
<p id="p-0001-en" num="0000">The invention is related to biomimetic gels that are prepared enzymatically, using a transglutaminase to cross-link polymer-peptide conjugates of rational design.</p>
>> read more

Methods of identifying non-specific inhibitors of biomolecules (Fri, 26 Nov 2004)
<p id="p-0001-en" num="0000">The present invention provides methods of identifying compounds that non-specifically inhibit biological reactions. The present invention further includes kits that facilitate this identification. In addition, complications of compounds for use in high throughput drug screening that have been evaluated by the disclosed methodology are also part of the present invention. Further, the invention provides methods for identifying a false positive compound previously identified as positive in a screening assay by measuring the activity of at least one biological activity in the presence and absence of a small molecule compound capable of inhibiting aggregate formation, e.g., digitonin.</p>
>> read more

Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts (Fri, 12 Nov 2004)
<p id="p-0001-en" num="0000">A catalyst system useful to polymerize and co-polymerize polar and non-polar olefin monomers is formed by in situ reduction with a reducing agent of a catalyst precursor comprising [in-line-formulae]{Cp*MRR′_n}⁺{A}⁻[/in-line-formulae] wherein Cp* is a cyclopentadienyl or substituted cyclopentadienyl moiety; M is an early transition metal; R is a C₁–C₂₀hydrocarbyl; R′ are independently selected from hydride, C₁–C₂₀hydrocarbyl, SiR″₃, NR″₂, OR″, SR″, GeR″₃, SnR″₃, and C═C-containing groups (R″=C₁–C₁₀hydrocarbyl); n is an integer selected to balance the oxidation state of M; and A is a suitable non-coordinating anionic cocatalyst or precursor. This catalyst system may form stereoregular olefin polymers including syndiotactic polymers of styrene and methylmethacrylate and isotactic copolymers of polar and nonpolar olefin monomers such as methylmethacrylate and styrene. </p>
>> read more

Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase (Wed, 22 Sep 2004)
<p id="p-00001-en">(1S, 3S)-3-Amino-4-difluoromethylene-1-cyclopentanoic acid illustrates a novel class of compounds as potent irreversible inhibitors of γ-aminobutyric acid aminotransferase (GABA-AT). The corresponding monofluoro-substituted compounds also are potent time-dependent inhibitors of GABA-AT.</p>
>> read more

VAPOR DEPOSITED ELECTRO-OPTIC FILMS SELF-ASSEMBLED THROUGH HYDROGEN BONDING (Fri, 17 Sep 2004)
The present invention introduces a novel route toward microstructural orientation into organic films, using multiple hydrogen-bonding to self-assemble chromophore molecules into electro-optic films in a net polar orientation. High­quality, thick films (up to micrometers) with molecular net dipole orientations can be fabricated under vacuum in hours. The film microstructure is intrinsically acentric; and the orientation is robust.
>> read more

Organic light-emitting diodes and methods for assembly and emission control (Fri, 14 May 2004)
<p id="p-0001-en" num="0000">New organic light-emitting diodes and related electroluminescent devices and methods for fabrication, using siloxane self-assembly techniques.</p>
>> read more

STERICALLY-AWKWARD β-LACTAMASE INHIBITORS (Fri, 07 May 2004)
6(7)-β-substituted β-lactam compounds as inhibitors of β-lactamase activity.
>> read more

ANTI-ANGIOGENIC FRAGMENTS OF PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) (Fri, 09 Apr 2004)
The present invention provides anti-angiogenic derived from pigment epithelium-derived factor (PEDF) pharmaceutical compositions comprising the peptides, and methods of preventing angiogenesis. Such methods are useful in treating angiogenesis-associated disorders and diseases.
>> read more

Encapsulation of nanotubes via self-assembled nanostructures (Fri, 06 Feb 2004)
<p id="p-0001-en" num="0000">This invention is directed to encapsulated nanotubes, methods of encapsulating carbon nanotubes, and uses for encapsulated nanotubes. Carbon nanotubes are encapsulated by self assembly of Uses of the present invention include making arrays as a basis for synthesis of carbon fibers.</p>
>> read more

Self-assembly and mineralization of peptide-amphiphile nanofibers (Fri, 30 Jan 2004)
<p id="p-0001-en" num="0000">Peptide-amphiphilic compositions capable of self-assembly into useful nanostructures.</p>
>> read more

Self-assembly of peptide-amphiphile nanofibers under physiological conditions (Fri, 02 Jan 2004)
<p id="p-0001-en" num="0000">Peptide amphiphile compounds, compositions and methods for self-assembly or nanofibrous network formation under neutral or physiological conditions.</p>
>> read more

Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts (Wed, 31 Dec 2003)
<p id="p-00001-en">A catalyst system useful to polymerize and co-polymerize polar and non-polar olefin monomers is formed by in situ reduction with a reducing agent of a catalyst precursor comprising</p> <p id="p-00002-en">{CP* MRR′_n}⁺{A}⁻</p> <p id="p-00003-en">wherein Cp* is a cyclopentadienyl or substituted cyclopentadienyl moiety; M is an early transition metal; R is a C₁-C₂₀hydrocarbyl; R′ are independently selected from hydride, C₁-C₂₀hydrocarbyl, SiR″₃, NR″₂, OR″, SR″, GeR″₃, SnR″₃, and C═C containing groups (R″═C₁-C₁₀hydrocarbyl); n is an integer selected to balance the oxidation state of M; and A is a suitable non-coordinating anionic cocatalyst or precursor. This catalyst system may form stereoregular olefin polymers including syndiotactic polymers of styrene and methylmethacrylate and isotactic copolymers of polar and nonpolar olefin monomers such as methylmethacrylate and styrene.</p>
>> read more

ENCAPSULATION OF NANOTUBES VIA SELF-ASSEMBLED NANOSTRUCTURES (Fri, 31 Oct 2003)
This invention is directed to encapsulated nanotubes, methods of encapsulating carbon nanotubes, and uses for encapsulated nanotubes. Carbon nanotubes are encapsulated by self assembly of Uses of the present invention include making arrays as a basis for synthesis of carbon fibers.
>> read more

Perfluoronaphthyl substituted boron containing catalyst activator (Wed, 22 Oct 2003)
<p id="p-00001-en">A catalyst activator particularly adapted for use in the activation of metal complexes of metals of Group 3-10 for polymerization of ethylenically unsaturated polymerizable monomers, especially olefins, comprising a neutral (Lewis acid) or charge separated (cation/anion pair) comprising a boron ligand containing a fluorinated organic group containing from 10 to 1000 non-hydrogen atoms.</p>
>> read more

ORGANIC LIGHT-EMITTING DIODES AND METHODS FOR ASSEMBLY AND ENHANCED CHARGE INJECTION (Fri, 26 Sep 2003)
New organic light-emitting diodes and related electroluminescent devices and methods for fabrication, using siloxane self-assembly techniques.
>> read more

SELF-ASSEMBLY OF PEPTIDE-AMPHIPHILE NANOFIBERS UNDER PHYSIOLOGICAL CONDITIONS (Fri, 29 Aug 2003)
Peptide amphiphile compounds, compositions and methods for self-assembly or nanofibrous network formation under neutral or physiological conditions.
>> read more

Solid-phase reactions (Fri, 01 Aug 2003)
<p id="p-0001-en" num="0000">The present invention relates to systems, compositions, and methods for the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. The present invention relates to methods for attaching nucleic acids to solid supports and modifying nucleic acids. For example, in some embodiments, the 5′ nuclease activity of a cleavage agent is used to cleave a cleavage structure formed on the solid support, the occurrence of the cleavage event indicating the presence of specific nucleic acid sequences.</p>
>> read more

Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts (Fri, 18 Jul 2003)
<p id="p-00001-en">A catalyst system useful to polymerize and co-polymerize polar and non-polar olefin monomers is formed by in situ reduction with a reducing agent of a catalyst precursor comprising</p> <p id="p-00002-en">{Cp*MRR′_n}⁺{A}⁻</p> <p id="p-00003-en">wherein Cp* is a cyclopentadienyl or substituted cyclopentadienyl moiety; M is an early transition metal; R is a C₁-C₂₀hydrocarbyl; R′ are independently selected from hydride, C₁-C₂₀hydrocarbyl, SiR″₃, NR″₂, OR″, SR″, GeR″₃, SnR″₃, and C═C-containing groups (R″=C₁-C₁₀hydrocarbyl); n is an integer selected to balance the oxidation state of M; and A is a suitable non-coordinating anionic cocatalyst or precursor. This catalyst system may form stereoregular olefin polymers including syndiotactic polymers of styrene and methylmethacrylate and isotactic copolymers of polar and nonpolar olefin monomers such as methylmethacrylate and styrene.</p>
>> read more

SELF-ASSEMBLY AND MINERALIZATION OF PEPTIDE-AMPHIPHILE NANOFIBERS (Fri, 04 Jul 2003)
Peptide-amphiphilic compositions capable of self-assembly into useful nanostructures.
>> read more

Solid-phase reactions (Fri, 27 Jun 2003)
<p id="p-0001-en" num="0000">The present invention relates to systems, compositions, and methods for the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. The present invention relates to methods for attaching nucleic acids to solid supports and modifying nucleic acids. For example, in some embodiments, the 5′ nuclease activity of a cleavage agent is used to cleave a cleavage structure formed on the solid support, the occurrence of the cleavage event indicating the presence of specific nucleic acid sequences.</p>
>> read more

Selective neuronal nitric oxide synthase inhibitors (Fri, 27 Jun 2003)
<p id="p-00001-en">Peptidomimetic compositions for selective inhibition of neuronal nitric oxide synthase.</p>
>> read more

N-type thiophene semiconductors (Fri, 02 May 2003)
<p id="p-00001-en">The new fluorocarbon-functionalized and/or heterocycle-modified polythiophenes, in particular, α,ω-diperfluorohexylsexithiophene DFH-6T can be straightforwardly prepared in high yield and purity. Introduction of such modifications to a thiophene core affords enhanced thermal stability and volatility, and increased electron affinity versus the unmodified compositions of the prior art. Evaporated films behave as n-type semiconductors, and can be used to fabricate thin film transistors with FET mobilities ˜0.01 cm²/Vs—some of the highest reported to date for n-type organic semiconductors.<chemistry id="chem-us-00001-en"><img he="N/A" wi="N/A" img-format="tif" id="emi-c00001-en" file="US06585914-20030701-C00001.TIF" img-content="chem" alt="embedded image"/></chemistry></p>
>> read more

Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts (Wed, 09 Apr 2003)
<p id="p-00001-en">A catalyst system useful to polymerize and co-polymerize polar and non-polar olefin monomers is formed by in situ reduction with a reducing agent of a catalyst precursor comprising</p> <p id="p-00002-en">{Cp*MRR′_n}⁺{A}⁻</p> <p id="p-00003-en">wherein Cp* is a cyclopentadienyl or substituted cyclopentadienyl moiety; M is an early transition metal; R is a C₁-C₂₀hydrocarbyl; R′ are independently selected from hydride, C₁-C₂₀hydrocarbyl, SiR″₃, NR″₂, OR″, SR″, GeR″₃, and SnR″₃containing groups (R″=C₁-C₁₀hydrocarbyl); n is an integer selected to balance the oxidation state of M; and A is a suitable non-coordinating anionic cocatalyst or precursor. This catalyst system may form stereoregular olefin polymers including syndiotactic polymers of styrene and methylmethacrylate and isotactic copolymers of polar and nonpolar olefin monomers such as methylmethacrylate and styrene.</p>
>> read more

ANTI-INFLAMMATORY AND PROTEIN KINASE INHIBITOR COMPOSITION AND METHOD OF USE (Fri, 07 Mar 2003)
A novel class of pyridazine compositions and related methods of use.
>> read more

Polypeptoid pulmonary surfactants (Fri, 28 Feb 2003)
<p id="p-0001-en" num="0000">The present invention provides spreading agents based on sequence-specific oligomers comprising a peptoid, a peptide-peptoid chimera, a retropeptoid or a retro(peptoid-peptide) chimera, and methods for using the same, including for the treatment of respiratory distress of the lungs. The spreading agents are sequence-specific oligomers, including retrosequence-specific oligomers, based on a peptide backbone, that are designed as analogs of surfactant protein-B or surfactant protein-C.</p>
>> read more

GABA and L-glutamic acid analogs for antiseizure treatment (Wed, 26 Feb 2003)
<p id="p-00001-en">A compound of the formula<chemistry id="chem-us-00001-en"><img he="N/A" wi="N/A" img-format="tif" id="emi-c00001-en" file="US06525096-20030225-C00001.TIF" img-content="chem" alt="embedded image"/></chemistry></p> <p id="p-00002-en">wherein R₁is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R₂is hydrogen or methyl; and R₃is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.</p>
>> read more

n-TYPE THIOPHENE SEMICONDUCTORS (Fri, 07 Feb 2003)
The new fluorocarbon-functionalized and/or heterocycle-modified polythiophenes, in particular, α,φ-diperfluohexylsexithiophene DFH-6T can be straightforwardly prepared in high yield and purity. Introduction of such modifications to a thiophene core affords enhanced thermal stability and volatility, and increased electron affinity versus the unmodified compositions of the prior art. Evaporated films behave as n-type semiconductors, and can be used to fabricate thin film transistors with FET mobilities ∼0.01 cm2/Vs--some of the highest reported to date for n-type organic semiconductors.
>> read more

ADHESIVE DOPA-CONTAINING POLYMERS AND RELATED METHODS OF USE (Fri, 31 Jan 2003)
3,4-Dihydroxyphenyl-L-alanine (DOPA) is an unusual amino acid found in mussel adhesive proteins (MAPs) that form tenacious bonds to various substrates under water. DOPA is believed to be responsible for the adhesive characteristics of MAPs. This invention relates to a route for the conjugation of DOPA moieties to various polymeric systems, including but not limited to poly(ethylene glycol) or poly(alkylene oxide) systems such as poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) block copolymers.
>> read more

SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS (Sat, 04 Jan 2003)
Peptidomimetic compositions for selective inhibition of neuronal nitric oxide synthase.
>> read more

Organic light-emitting diodes and methods for assembly and emission control (Fri, 06 Dec 2002)
<p id="p-00001-en">New organic light-emitting diodes and related electroluminescent devices and methods for fabrication, using siloxane self-assembly techniques.</p>
>> read more

Inhibitors of β-lactamases and uses therefor (Wed, 11 Sep 2002)
<p id="p-00001-en">The invention provides novel non-β-lactam inhibitors of β-lactamases. In particular, the invention provides such inhibitors which are boronic acids of formula (1) which is set forth in the specification. These compounds may be used with β-lactam antibiotics to treat β-lactam-antibiotic-resistant bacterial infections. These compounds are also antibacterial by themselves. Finally, the invention provides a pharmaceutical composition comprising these compounds.</p>
>> read more

Organosilicon compounds and uses thereof (Wed, 10 Jul 2002)
<p id="p-00001-en">A compound of the formula:<chemistry id="chem-us-00001-en"><img he="N/A" wi="N/A" img-format="tif" id="emi-c00001-en" file="US06416861-20020709-C00001.TIF" img-content="chem" alt="embedded image"/></chemistry></p> <p id="p-00002-en">and a resin-bound compound of the formula:<chemistry id="chem-us-00002-en"><img he="N/A" wi="N/A" img-format="tif" id="emi-c00002-en" file="US06416861-20020709-C00002.TIF" img-content="chem" alt="embedded image"/></chemistry></p> <p id="p-00003-en">and their use in combinatorial chemistry and in the synthesis of compounds comprising at least one aromatic moiety is described, where R¹, R², R³, R⁴, R⁵, R⁶, R⁷, L¹, P, Ar¹, and X are as herein defined.</p>
>> read more

GABA and L-glutamic acid analogs for antiseizure treatment (Wed, 03 Jul 2002)
<p id="p-00001-en">A compound of the formula<chemistry id="chem-us-00001-en"><img he="N/A" wi="N/A" img-format="tif" id="emi-c00001-en" file="US06414024-20020702-C00001.TIF" img-content="chem" alt="embedded image"/></chemistry></p> <p id="p-00002-en">wherein R₁is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R₂is hydrogen or methyl; and R₃is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.</p>
>> read more

IMMUNOGENIC CANCER PEPTIDES AND USES THEREOF (Fri, 21 Jun 2002)
This invention relates to novel general methods and compositions that provide cancer-specific or highly cancer-associated antigens useful for diagnosis and treatment of cancer.
>> read more

Organic light-emitting diodes and methods for assembly and emission control (Wed, 05 Jun 2002)
<p id="p-00001-en">New organic light-emitting diodes and related electroluminescent devices and methods for fabrication, using siloxane self-assembly techniques.</p>
>> read more

(Polyfluoroaryl) fluoroanions of aluminum, gallium, and indium of enhanced utility, uses thereof, and products based thereon (Wed, 15 May 2002)
<p id="p-00001-en">The (polyfluoroaryl)fluoroanions of aluminum, gallium, and indium are novel weakly coordinating anions which are highly fluorinated. (Polyfluoroaryl)fluoroanions of one such type contain at least one ring substituent other than fluorine. These (polyfluoroaryl)fluoroanions of aluminum, gallium, and indium have greater solubility in organic solvents, or have a coordinative ability essentially equal to or less than that of the corresponding (polyfluoroaryl)fluoroanion of aluminum, gallium, or indium in which the substituent is replaced by fluorine. Another type of new (polyfluoroaryl)fluoroanion of aluminum, gallium, and indium have 1-3 perfluorinated fused ring groups and 2-0 perfluorophenyl groups. When used as a cocatalyst in the formation of novel catalytic complexes with d- or f-block metal compounds having at least one leaving group such as a methyl group, these anions, because of their weak coordination to the metal center, do not interfere in the ethylene polymerization process, while affecting the propylene process favorably, if highly isotactic polypropylene is desired. Thus, the (polyfluoroaryl)fluoroanions of aluminum, gallium, and indium of this invention are useful in various polymerization processes such as are described.</p>
>> read more

n-type thiophene semiconductors (Fri, 10 May 2002)
<p id="p-00001-en">The new fluorocarbon-functionalized polythiophenes, in particular, α,ω-diperfluorohexylsexithiophene DFH-6T (1) can be straightforwardly prepared in high yield and purified by gradient sublimation. Introduction of perfluorocarbon chains on the thiophene core affords enhanced thermal stability and volatility, and increased electron affinity versus the fluorine-free analog 2. Evaporated films of 1, for example, behave as n-type semiconductors, and can be used to fabricate thin film transistors with FET mobilities on the order of ˜0.01 cm²/Vs—some of the highest reported to date for n-type organic semiconductors.<chemistry id="chem-us-00001-en"><img he="N/A" wi="N/A" img-format="tif" id="emi-c00001-en" file="US06608323-20030819-C00001.TIF" img-content="chem" alt="embedded image"/></chemistry></p>
>> read more

Therapeutic methods that target fractalkine or CX3CR1 (Fri, 10 May 2002)
<p id="p-a-0001-en">The invention relates to antagonists of CX3C chemokine receptor 1 (CX3CR1) function, antagonists of fractalkine function and to therapeutic methods employing the antagonists. The invention also relates to a method for diagnosing rheumatoid arthritis. </p>
>> read more

Therapeutic methods that target fractalkine or CX3CR1 (Fri, 10 May 2002)
<p id="p-a-0001-en">The invention relates to antagonists of CX3C chemokine receptor 1 (CX3CR1) function, antagonists of fractalkine function and to therapeutic methods employing the antagonists. The invention also relates to a method for diagnosing rheumatoid arthritis. </p>
>> read more

GABA and L-glutamic acid analogs for antiseizure treatment (Wed, 20 Mar 2002)
<p id="p-00001-en">A compound of the formula<chemistry id="chem-us-00001-en"><img he="N/A" wi="N/A" img-format="tif" id="emi-c00001-en" file="US06359169-20020319-C00001.TIF" img-content="chem" alt="embedded image"/></chemistry></p> <p id="p-00002-en">wherein R₁is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R₂is hydrogen or methyl; and R₃is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.</p>
>> read more

n-TYPE THIOPHENE SEMICONDUCTORS (Fri, 01 Feb 2002)
The new fluorocarbon-functionalized polythiophenes, in particular, α,φ-diperfluorohexylsexithiophene DFH-6T (1) can be straightforwardly prepared in high yield and purified by gradient sublimation. Introduction of perfluorocarbon chains on the thiophene core affords enhanced thermal stability and volatility, and increased electron affinity versus the fluorine-free analog 2. Evaporated films of 1, for example, behave as n-type semiconductors, and can be used to fabricate thin film transistors with FET mobilities on the order of ∩ 0.01 cm2/Vs -- some of the highest reported to data for n-type organic semiconductors. (I) DFH-6T (1), R=nC6F13 DH-6T (2), R=nC6H13 6T (3), R=H.
>> read more

GABA and L-glutamic acid analogs for antiseizure treatment (Wed, 30 Jan 2002)
<p id="p-00001-en">A compound of the formula<chemistry id="chem-us-00001-en"><img he="N/A" wi="N/A" img-format="tif" id="emi-c00001-en" file="US06342529-20020129-C00001.TIF" img-content="chem" alt="embedded image"/></chemistry></p> <p id="p-00002-en">wherein R₁is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R₂is hydrogen or methyl; and R₃is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.</p>
>> read more

Organo-Lewis acid as cocatalyst for cationic homogeneous Ziegler-Natta olefin polymerizations (Fri, 25 Jan 2002)
<p id="p-00001-en">Organo-Lewis acids of the formula BR′R″₂wherein B is boron, R′ is fluorinated biphenyl, and R″ is a fluorinated phenyl, fluorinated biphenyl, or fluorinated polycyclic fused ring group, and cationic metallocene complexes formed therewith. Such complexes are useful as polymerization catalysts.</p>
>> read more

Organo-Lewis acids of enhanced utility, uses thereof, and products based thereon (Fri, 26 Oct 2001)
<p id="p-00001-en">The organo-Lewis acids are novel triarylboranes which are are highly fluorinated. Triarylboranes of one such type contain at least one ring substituent other than fluorine. These organoboranes have a Lewis acid strength essentially equal to or greater than that of the corresponding organoborane in which the substituent is replaced by fluorine, or have greater solubility in organic solvents. Another type of new organoboranes have 1-3 perfluorinated fused ring groups and 2-0 perfluorophenyl groups. When used as a cocatalyst in the formation of novel catalytic complexes with d- or f-block metal compounds having at least one leaving group such as a methyl group, these triorganoboranes, because of their ligand abstracting properties, produce corresponding anions which are capable of only weakly, if at all, coordinating to the metal center, and thus do not interfere in various polymerization processes such as are described.</p>
>> read more

3D MODEL OF AN FC EPSILON RECEPTOR ALPHA CHAIN-IGE FC REGION COMPLEX (Fri, 21 Sep 2001)
The present invention includes three-dimensional models of complexes between antibody receptor proteins, such as FcεRIα proteins, and antibodies, such as Fc-Cε3/Cε4 regions of IgE antibodies, as well as methods to produce such models. The present invention also includes muteins having increased stability and/or antibody binding activity, as well as methods to produce such muteins, preferably using information derived from three-dimensional models of the present invention. Also included are nucleic acid sequences encoding muteins of the present invention and use of those sequences to produce such muteins. Also included is the use of the model to identify compounds that inhibit the binding of an antibody receptor protein to an antibody. The present invention also includes uses of such muteins and inhibitory compounds, for example, in methods to diagnose and protect animals from allergy and other abnormal immune response.
>> read more

THREE-DIMENSIONAL MODEL OF A Fc REGION OF AN IgE ANTIBODY AND USES THEREOF (Fri, 21 Sep 2001)
The present invention includes three-dimensional models of antibodies, such as Fc-Cε3/Cε4 regions of IgE antibodies, as well as methods to produce such models. The present invention also includes muteins having increased stabiltiy and/or antibody receptor binding activity, as well as methods to produce such muteins, preferably using information derived from three-dimensional models of the present invention. Also included are nucleic acid sequences encoding muteins of the present invention and use of those sequences to produce such muteins. Also included is the use of themodel to identify compounds that inhibit the binding of an antibody receptor protein to an antibody. The present invention also includes uses of such muteins and inhibitory compounds, for example, in methods to diagnose and protect animals from allergy and othter abnormal immune responses.
>> read more

GABA and L-glutamic acid analogs for antiseizure treatment (Wed, 19 Sep 2001)
<p id="p-00001-en">A compound of the formula<chemistry id="chem-us-00001-en"><img he="N/A" wi="N/A" img-format="tif" id="emi-c00001-en" file="US06291526-20010918-C00001.TIF" img-content="chem"/></chemistry></p> <p id="p-00002-en">wherein R₁is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R₂is hydrogen or methyl; and R₃is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.</p>
>> read more

Organo-Lewis acids of enhanced utility, uses thereof, and products based thereon (Wed, 19 Sep 2001)
<p id="p-00001-en">The organo-Lewis acids are novel triarylboranes which are highly fluorinated. Triarylboranes of one such type contain at least one ring substituent other than fluorine. These organoboranes have a Lewis acid strength essentially equal to or greater than that of the corresponding organoborane in which the substituent is replaced by fluorine, or have greater solubility in organic solvents. Another type of new organoboranes have 1-3 perfluorinated fused ring groups and 2-0 perfluorophenyl groups. When used as a cocatalyst in the formation of novel catalytic complexes with d- or f-block metal compounds having at least one leaving group such as a methyl group, these triorganoboranes, because of their ligand abstracting properties, produce corresponding anions which are capable of only weakly, if at all, coordinating to the metal center, and thus do not interfere in various polymerization processes such as are described.</p>
>> read more

THERAPEUTIC METHODS THAT TARGET FRACTALKINE OR CX3CR1 (Fri, 24 Aug 2001)
The invention relates to antagonists of CX3C chemokine receptor 1 (CX3CR1) function, antagonists of fractalkine function and to therapeutic methods employing the antagonists. The invention also relates to a method for diagnosing rheumatoid arthritis.
>> read more

POLYPEPTOID PULMONARY SURFACTANTS (Fri, 24 Aug 2001)
The present invention provides spreading agents based on sequence-specific oligomers comprising a peptoid, a peptide-peptoid chimera, a retropeptoid or a retro(peptoid-peptide) chimera, and methods for using the same, including for the treatment of respiratory distress of the lungs. The spreading agents are sequence-specific oligomers, including retrosequence-specific oligomers, based on a peptide backbone, that are designed as analogs of surfactant protein-B or surfactant protein-C.
>> read more

Inhibition of nitric oxide synthase by amino acids and dipeptides (Wed, 15 Aug 2001)
<p id="p-00001-en">Methods and compositions for inhibiting at least one isoform of nitric oxide synthase are provided. Pharmaceutical compositions include derivatives of arginine as well as dipeptides and dipeptide analogs that contain nitroarginine or another unnatural amino acid. Compositions can be used to selectively inhibit particular isoforms of nitric oxide synthase.</p>
>> read more

Organo-Lewis acid as cocatalyst for cationic homogeneous Ziegler-Natta olefin polymerizations (Wed, 15 Aug 2001)
<p id="p-00001-en">Organo-Lewis acids of the formula BR′R″₂wherein B is boron, R′ is fluorinated biphenyl, and R″ is a fluorinated phenyl, fluorinated biphenyl, or fluorinated polycyclic fused ring group, and cationic metallocene complexes formed therewith. Such complexes are useful as polymerization catalysts.</p>
>> read more

Catalyst activator (Wed, 01 Aug 2001)
<p id="p-00001-en">A catalyst activator particularly adapted for use in the activation of metal complexes of metals of Group 3-10 for polymerization of ethylenically unsaturated polymerizable monomers, especially olefins, comprising two Group 13 metal or metalloid atoms and a ligand structure including at least one bridging group connecting ligands on the two Group 13 metal or metalloid atoms.</p>
>> read more

GABA and L-glutamic acid analogs for antiseizure treatment (Wed, 18 Jul 2001)
<p id="p-00001-en">A compound of the formula<chemistry id="chem-us-00001-en"><img he="N/A" wi="N/A" img-format="tif" id="emi-c00001-en" file="US06262120-20010717-C00001.TIF" img-content="chem"/></chemistry></p> <p id="p-00002-en">wherein R₁is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R₂is hydrogen or methyl; and R₃is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.</p>
>> read more

(Polyfluoroaryl)fluoroanions of aluminum, gallium, and indium of enhanced utility, uses thereof, and products based thereon (Wed, 18 Jul 2001)
<p id="p-00001-en">The (polyfluoroaryl)fluoroanions of aluminum, gallium, and indium are novel weakly coordinating anions which are are highly fluorinated. (Polyfluoroaryl)fluoroanions of one such type contain at least one ring substituent other than fluorine. These (polyfluoroaryl)fluoroanions of aluminum, gallium, and indium have greater solubility in organic solvents, or have a coordinative ability essentially equal to or less than that of the corresponding (polyfluoroaryl)fluoroanion of aluminum, gallium, or indium in which the substituent is replaced by fluorine. Another type of new (polyfluoroaryl)fluoroanion of aluminum, gallium, and indium have 1-3 perfluorinated fused ring groups and 2-0 perfluorophenyl groups. When used as a cocatalyst in the formation of novel catalytic complexes with d- or f-block metal compounds having at least one leaving group such as a methyl group, these anions, because of their weak coordination to the metal center, do not interefere in the ethylene polymerization process, while affecting the the propylene process favorably, if highly isotactic polypropylene is desired. Thus, the (polyfluoroaryl)fluoroanions of aluminum, gallium, and indium of this invention are useful in various polymerization processes such as are described.</p>
>> read more

GABA and L-glutamic acid analogs for antiseizure treatment (Wed, 04 Jul 2001)
<p id="p-00001-en">A compound of the formula<chemistry id="chem-us-00001-en"><img he="N/A" wi="N/A" img-format="tif" id="emi-c00001-en" file="US06255345-20010703-C00001.TIF" img-content="chem"/></chemistry></p> <p id="p-00002-en">wherein R₁is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R₂is hydrogen or methyl; and R₃is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.</p>
>> read more

Supported organometallic catalysts for hydrogenation and Olefin Polymerization (Wed, 23 May 2001)
<p id="p-00001-en">Novel heterogeneous catalysts for the which hydrogenation of olefins and arenes with high conversion rates under ambient conditions and the polymerization of olefins have been developed. The catalysts are synthesized from Ziegler-type precatalysts by supporting them on sulfate-modified zirconia.</p>
>> read more

Synthesis and use of (perfluoroaryl) fluoro-aluminate anion (Wed, 09 May 2001)
<p id="p-00001-en">A trityl perfluorophenyl alumninate such as tris(2,2′,2″-nonafluorobiphenyl)-fluoroaluminate (PBA^⊖) and its role as a cocatalyst in metallocene-mediated olefin polymerization is disclosed. Gallium and indium analogs are also disclosed, as are analogs with different anyl groups or different numbers of flourine atoms thereon.</p>
>> read more

(Polyfluoroaryl) fluoroanions of aluminum, gallium, and indium of enhanced utility, uses thereof, and products based thereon (Wed, 18 Apr 2001)
<p id="p-00001-en">The (polyfluoroaryl)fluoroanions of aluminum, gallium, and indium are novel weakly coordinating anions which are highly fluorinated. (Polyfluoroaryl)fluoroanions of one such type contain at least one ring substituent other than fluorine. These (polyfluoroaryl)fluoroanions of aluminum, gallium, and indium have greater solubility in organic solvents, or have a coordinative ability essentially equal to or less than that of the corresponding (polyfluoroaryl)fluoroanion of aluminum, gallium, or indium in which the substituent is replaced by fluorine. Another type of new (polyfluoroaryl)fluoroanion of aluminum, gallium, and indium have 1-3 perfluorinated fused ring groups and 2-0 perfluorophenyl groups. When used as a cocatalyst in the formation of novel catalytic complexes with d- or f-block metal compounds having at least one leaving group such as a methyl group, these anions, because of their weak coordination to the metal center, do not interfere in the ethylene polymerization process, while affecting the propylene process favorably, if highly isotactic polypropylene is desired. Thus, the (polyfluoroaryl)fluoroanions of aluminum, gallium, and indium of this invention are useful in various polymerization processes such as are described.</p>
>> read more

SELF-ASSEMBLING COMPOUNDS AND USE OF THE SAME TO INDUCE ORDER IN ORGANIC MEDIA (Fri, 30 Mar 2001)
Self-assembling compounds capable of forming birefringent gels when added to an organic medium in an amount of about 0.05 % to about 2 % by weight are disclosed. A birefringent gel containing a self-assembling compound and an organic monomer can be polymerized to produce an optically birefringent polymer. The birefringent polymer can be melted to provide a birefringent melt that then can be formed into an article of manufacture, like an optical fiber.
>> read more

Gamma amino butyric acid analogs and optical isomers (Wed, 07 Mar 2001)
<p id="p-00001-en">A compound of the formula<chemistry id="chem-us-00001-en"><img he="N/A" wi="N/A" img-format="tif" id="emi-c00001-en" file="US06197819-20010306-C00001.TIF" img-content="chem"/></chemistry></p> <p id="p-00002-en">wherein R₁is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R₂is hydrogen or methyl; and R₃is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.</p>
>> read more

Inhibitors of β-lactamases and uses therefor (Wed, 07 Feb 2001)
<p id="p-00001-en">The invention provides novel non-β-lactam inhibitors of β-lactamases. In particular, the invention provides such inhibitors which are boronic acids of formula (1) which is set forth in the specification. These compounds may be used with β-lactam antibiotics to treat β-lactam-antibiotic-resistant bacterial infections. These compounds are also antibacterial by themselves. Finally, the invention provides a pharmaceutical composition comprising these compounds.</p>
>> read more

CYCLOPENTADIENYL-CONTAINING LOW-VALENT EARLY TRANSITION METAL OLEFIN POLYMERIZATION CATALYSTS (Fri, 12 Jan 2001)
A catalyst system useful to polymerize and co-polymerize polar and non-polar olefin monomers is formed by in situ reduction with a reducing agent of a catalyst precursor comprising {Cp* MRR'n}+{A}- wherein Cp* is a cyclopentadienyl or substituted cyclopentadienyl moiety; M is an early transition metal; R is a C¿1?-C20 hydrocarbyl; R' are independently selected from hydride, C1-C¿20 hydrocarbyl, SiR''3, NR''2, OR'', SR'', GeR''3, SnR''3, and C=C groups (R''=C1-C10 hydrocarbyl); n is an integer selected to balance the oxidation state of M; and A is a suitabale non-coordinating anionic cocatalyst or precursor. This catalyst system may form stereoregular olefin polymers including syndiotactic polymers of styrene and methylmethacrylate and isotactic copolymers of polar and nonpolar olefin monomers such as methylmethacrylate and styrene.
>> read more

GABA and L-glutamic acid analogs for antiseizure treatment (Wed, 01 Nov 2000)
<p>A compound of the formula ##STR1## wherein R.sub.1 is a straight branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R.sub.2 is hydrogen or methyl; and R.sub.3 is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.</p>
>> read more

Synthesis and use of (polyfluoroaryl)fluoroanions of aluminum, gallium and indium (Wed, 11 Oct 2000)
<p>Salts of (polyfluoroaryl)fluoroanions of aluminum, gallium, and indium are described. The (polyfluoroaryl)fluoroanions have the formula [ER'R"R'"F].sup..crclbar. wherein E is aluminum, gallium, or indium, wherein F is fluorine, and wherein R', R", and R'" is each a fluorinated phenyl, fluorinated biphenyl, or fluorinated polycyclic group. -GOVT PAR This invention was made with Government support under Contract No. DE-FG02-86ER13511 awarded by the Department of Energy. The Government has certain rights in this invention.</p>
>> read more

GABA and L-glutamic acid analogs for antiseizure treatment (Wed, 13 Sep 2000)
<p>A compound of the formula ##STR1## wherein R.sub.1 is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R.sub.2 is hydrogen or methyl; and R.sub.3 is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.</p>
>> read more

ORGANOSILICON COMPOUNDS AND USES THEREOF (Fri, 25 Aug 2000)
A compound of formula (I) and a resin-bound compound of formula (II): and their use in combinatorial chemistry and in the synthesis of compounds comprising at least one aromatic moiety is described, where R?1, R2, R3, R4, R5, R6, R7, L1, P, Ar1¿, and X are as herein defined.
>> read more

Organo-Lewis acid as cocatalyst for cationic homogenous metallocene Ziegler-Natta olefin polymerizations (Wed, 12 Jul 2000)
<p>The synthesis of the organo-Lewis acid perfluorobiphenylborane (PBB) and the activation of metallocenes for the formation of a variety of highly active homogeneous Ziegler-Natta metallocene olefin polymerization, copolymerization and ring-opening polymerization catalysts is described. -GOVT PAR This invention was made with Government support under Contract No. DE-FG02-86ER13511 awarded by the Department of Energy. The Government has certain rights in this invention.</p>
>> read more

INHIBITORS OF β-LACTAMASES AND USES THEREFOR (Fri, 23 Jun 2000)
The invention provides novel non-β-lactam inhibitors of β-lactamases. In particular, the invention provides such inhibitors which are boronic acids of formula (1) which is set forth in the specification. These compounds may be used with β-lactam antibiotics to treat β-lactam-antibiotic-resistant bacterial infections. Finally, the invention provides a pharmaceutical composition comprising these compounds.
>> read more

INHIBITORS OF β-LACTAMASES AND USES THEREFOR (Fri, 23 Jun 2000)
The invention provides novel non-β-lactam inhibitors of β-lactamases. In particular, the invention provides such inhibitors which are boronic acids of formula (1) which is set forth in the specification. These compounds may be used with β-lactam antibiotics to treat β-lactam-antibiotic-resistant bacterial infections. Finally, the invention provides a pharmaceutical composition comprising these compounds.
>> read more

Silyl-terminated polymer and method for preparing silyl-terminated polyolefins (Wed, 21 Jun 2000)
<p>There is disclosed a method for synthesizing polyolefins having a silyl group at one terminus, the method comprising reacting a monomer of an a-olefin (C.ltoreq.3.ltoreq.10) and a tetrasubstituted silyl radical in the presence of a metallocene catalyst. -GOVT PAR This invention is made with government support under the National Science Foundation, Grant # CHE 910411. The government has certain rights in the invention.</p>
>> read more

Inhibitors of .beta.-lactamases and uses therefor (Wed, 14 Jun 2000)
<p>The invention provides novel non-.beta.-lactam inhibitors of .beta.-lactamases. In particular, the invention provides such inhibitors which are boronic acids of formula (1) which is set forth in the specification. These compounds may be used with .beta.-lactam antibiotics to treat .beta.-lactam-antibiotic-resistant bacterial infections. These compounds are also antibacterial by themselves. Finally, the invention provides a pharmaceutical composition comprising these compounds.</p>
>> read more

Silyl-terminated polymer and method for preparing silyl-terminated polyolefins (Wed, 14 Jun 2000)
<p>There is disclosed a method for synthesizing polyolefins having a silyl group at one terminus, the method comprising reacting a monomer of an .alpha.-olefin (C.ltoreq.3.ltoreq.10) and a tetrasubstituted silyl radical in the presence of a metallocene catalyst. -GOVT PAR This invention is made with government support under Grant No. CHE 910 4112 awarded by the National Science Foundation. The government has certain rights in the invention.</p>
>> read more

Saturated tricyclic ligand containing metal complexes and olefin polymerization process (Wed, 22 Mar 2000)
<p>Bridged, group 4 Metal complexes useful as olefin polymerization catalyst components corresponding to the formula: L.sub.1 ZL.sub.2 MX.sub.m X'.sub.n PAL or a dimer, solvated adduct, chelated derivative or mixture thereof, wherein: PA1 L.sub.1 is a partially saturated tricyclic group, especially octahydrofluorenyl, PA1 L.sub.2 is a substituted cyclopentadienyl group that is bound to M by means of delocalized .pi.-electrons, said cyclopentadienyl group being substituted at one and only one of its two distal positions with a bulky ligand group, PA1 Z is divalent bridging substituent, PA1 X each occurrence is a monovalent, anionic moiety having up to 40 non-hydrogen atoms, optionally, two X groups may be covalently bound together forming a divalent dianionic moiety having both valences bound to M, or, optionally 2 X groups may be covalently bound together to form a neutral, conjugated or nonconjugated diene that is bonded to M by means of delocalized .pi.-electrons (whereupon M is in the +2 oxidation state), or further optionally one or more X and one or more X' groups may be bonded together thereby forming a moiety that is both covalently bound to M and coordinated thereto; PA1 m is 1 or 2 and is equal to two less than the formal oxidation state of M, except when 2 X groups together form a neutral conjugated or non-conjugated diene that is .pi.-bonded to M, in which case m is equal to the formal oxidation state of M; PA1 X' is a neutral ligand having up to 20 non-hydrogen atoms, and n is a number from 0 to 3.</p>
>> read more

Self-assembled superlattices and waveguides prepared for use therewith (Wed, 08 Mar 2000)
<p>One manner of construction of robust, thin film materials with large second-order optical nonlinearities is the covalent self-assembly of aligned arrays of high-.beta. molecular chromophores into multilayer superlattices. the dispersion of the large second harmonic generation (SHG) response in a self-assembled (SA) film containing stilbazolium chromophore building blocks is disclosed, as well as the fabrication of SHG waveguides with such materials.</p>
>> read more

GABA and L-glutamic acid analogs for antiseizure treatment (Wed, 23 Feb 2000)
<p>A compound of the formula ##STR1## wherein R.sub.1 is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R.sub.2 is hydrogen or methyl; and R.sub.3 is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are also disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are further disclosed.</p>
>> read more

MURINE HYBRIDOME LYM-1 AND DIAGNOSTIC ANTIBODY PRODUCED THEREBY (Thu, 23 Sep 1999)

>> read more

Catalyst system comprising an aryloxyaluminoxane containing an electron withdrawing group (Wed, 18 Aug 1999)
<p>Aryloxyaluminoxanes containing the unit ##STR1## where R is unsubstituted or substituted aryl, such as phenyl or naphthyl, are useful as a cocatalysts in Ziegler-Natta and Kaminsky-type olefin polymerization catalysts. They can be formed by reaction of a source of water with an organoaluminum compound containing the desired aryloxy moiety or by reaction of preformed aluminoxane with an organic compound, such as a phenol, containing such a moiety.</p>
>> read more

Oligonucleotides having modified internucleoside linkages or terminal amino group (Wed, 04 Aug 1999)
<p>Novel oligonucleotides, method for improving the hybridization properties of oligonucleotides and novel processes for preparing 3'-phosphorylated oligonucleotides.</p>
>> read more

.sup.23 NA and .sup.39 K imaging of the heart (Wed, 09 Jun 1999)
<p>Methods for increasing the efficiency of .sup.23 Na and .sup.39 K imaging of biological tissue are provided. For maximum efficiency, the receiver bandwidth is set equal to or less than the quantity N.sub.ro /T*2. Methods for assessing cardiac tissue viability using .sup.23 Na imaging are also provided. -GOVT PAR Funds used to support the studies disclosed herein were provided in part by the United States Government (NIH-NHLBI R29-HL53411). The United States government, therefore, may have certain rights in the invention.</p>
>> read more

CATALYST ACTIVATOR (Fri, 12 Feb 1999)
A catalyst activator particularly adapted for use in the activation of metal complexes of metals of Group 3-10 for polymerization of ethylenically unsaturated polymerizable monomers, especially olefins, comprising two Group 13 metal or metalloid atoms and a ligand structure including at least one bridging group connecting ligands on the two Group 13 metal or metalloid atoms.
>> read more

PERFLUORONAPHTHYL SUBSTITUTED BORON CONTAINING CATALYST ACTIVATOR (Fri, 12 Feb 1999)
A catalyst activator particularly adapted for use in the activation of metal complexes of metals of Group 3-10 for polymerization of ethylenically unsaturated polymerizable monomers, especially olefins, comprising a neutral (Lewis acid) or charge separated (cation/anion pair) comprising a boron ligand containing a fluorinated organic group containing from 10 to 100 non-hydrogen atoms.
>> read more

Cationic phospholipids for transfection (Wed, 06 Jan 1999)
<p>A novel class of cationic phospholipids and novel method for their synthesis are disclosed. The class of phospholipids comprises phosphotriester derivatives of phosphoglycerides and sphingolipids. It has been unexpectedly found that liposomes comprising one or more of these cationic phospholipids are effective in the lipofection of nucleic acids. These novel phospholipids are particularly attractive because of they are not only effective in lipofection, but are extremely cheap and easy to make.</p>
>> read more

Phenolate constrained geometry polymerization catalyst and method for preparing (Wed, 06 Jan 1999)
<p>The subject invention involves a method of preparing and the constrained geometry catalyst thereby prepared of the general formula Ar'R4(O)Ar"R'.sub.4 M(CH.sub.2 Ph).sub.2 where Ar' is a phenyl or naphthyl group; Ar" is a cyclopentadienyl or indenyl group, R and R' are H or alkyl substituents (C.ltoreq.10) and M is Ti, Zr or Hf. The synthetic method involves a simple alkane elimination approach which permits a "one-pot" procedure. The catalyst, when combined with a cocatalyst such as Pb.sub.3 C.sup.+ B(Ar.sub.3.sup.F).sub.4 BAr.sub.3.sup.F or methyl alumoxane where Ar.sup.F is a fluoroaryl group, is an effective catalyst for the polymerization of .alpha.-olefins such as ethylene, propylene and styrene. -GOVT PAR This invention was made with Government support under Contract No. DE-FG02-86ER13511 awarded by the Department of Energy. The Government has certain rights in this invention.</p>
>> read more

Organo-Lewis acid as cocatalyst for cationic homogeneous Ziegler-Natta olefin polymerizations (Wed, 06 Jan 1999)
<p>A cationic metallocene complex with trisperfluorobiphenyl borate for use as a polymerization catalyst. -GOVT PAR This invention was made with Government support under Contract No. DE-FG02-86ER13511 awarded by the Department of Energy. The Government has certain rights in this invention.</p>
>> read more

Synthesis and use of (perfluoroaryl) fluoro-aluminate anion (Wed, 30 Dec 1998)
<p>A trityl perfluorophenyl alumninate such as tris(2,2',2"-nonafluorobiphenyl) fluoroaluminate (PBA.sup.-) and its role as a cocatalyst in metallocene-mediated olefin polymerization is disclosed. -GOVT PAR This invention was made with Government support under Contract No. DE-FG02-86ER13511 awarded by the Department of Energy. The Government has certain rights in this invention.</p>
>> read more

INHIBITORS OF β-LACTAMASES AND USES THEREFOR (Fri, 18 Dec 1998)
The invention provides novel non-β-lactam inhibitors of β-lactamases. In particular, the invention provides such inhibitors which are boronic acids of formula (1) which is set forth in the specification. These compounds may be used with β-lactam antibiotics to treat β-lactam-antibiotic-resistant bacterial infections. These compounds are also antibacterial by themselves. Finally, the invention provides a pharmaceutical composition comprising these compounds.
>> read more

SILYL-TERMINATED POLYMER AND METHOD FOR PREPARING SILYL-TERMINATED POLYOLEFINS (Fri, 18 Dec 1998)
There is disclosed a method for synthesizing polyolefins having a silyl group at one terminus, the method comprising reacting an a-olefin (C≤ 3 ≤ 10) and a tetrasubstituted silyl radical in the presence of a metallocene catalyst and a co-catalyst. Examples of silane compounds: phenylsilane, diphenylsilane, phenylmethylsilane, pentamethyldisiloxane, methylsilane, diethylsilane and dimethylsilane.
>> read more

Gaba and L-glutamic acid analogs for antiseizure treatment (Wed, 09 Dec 1998)
<p>A compound of the formula ##STR1## wherein R.sub.1 is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R.sub.2 is hydrogen or methyl; and R.sub.3 is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed. -GOVT PAC GRANT INFORMATION PAR This invention was made with Government support under Grant No. NS15703 awarded by the National Institutes of Health. The Government has certain rights in the invention.</p>
>> read more

Organic light-emitting dioddes and methods for assembly and emission control (Wed, 11 Nov 1998)
<p>New organic light-emitting diodes and related electroluminescent devices and methods for fabrication, using siloxane self-assembly techniques. -GOVT PAC CONTRACTUAL ORIGIN OF INVENTION PAR The United States Government has rights in this invention pursuant to Grant No. N000149511319 from the Office of Naval Reserve to Northwestern University and Grant No. DMR9120521 from the National Science Foundation to Northwestern University.</p>
>> read more

INHIBITION OF NITRIC OXIDE SYNTHASE BY AMINO ACIDS AND DIPEPTIDES (Fri, 06 Nov 1998)
Methods and compositions for inhibiting at least one isoform of nitric oxide synthase are provided. Pharmaceutical compositions include derivatives of arginine as well as dipeptides and dipeptide analogs that contain nitroarginine or another unnatural amino acid. Compositions can be used to selectively inhibit particular isoforms of nitric oxide synthase.
>> read more

?23Na AND 39¿K IMAGING OF THE HEART (Fri, 23 Oct 1998)
Methods for increasing the efficiency of ?23Na and 39¿K imaging of biological tissue are provided. For maximum efficiency, the receiver bandwidth is set equal to or less than the quantity N¿ro/T?*2. Methods for assessing cardiac tissue viability using 23Na imaging are also provided.
>> read more

High oxidation state metal oxo complexes of the PHAB ligand (Wed, 29 Jul 1998)
<p>The present invention provides a new tetradentate bis-amido bis-alkoxo, 1,2-(bis-2,20diphenyl-2-hydroxyethanamido)benzene (H.sub.4 PHAB) and various derivatives thereof. This ligand is able to stabilize high valen metal oxo complexes by providing strong sigma donor ligands and through the use of steric bulk to prevent decomposition via formation of the .mu.-oxo dimers. Disclosed are novel metal oxo structural chemistry and oxidation reactions carried out with the novel metal oxo complexes. -GOVT PAR The U.S. Government owns rights in the present invention pursuant to the National Science Foundation Presidential Young Investigator Award CHE8657704.</p>
>> read more